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Abstract 
Regulatory agencies warn about acute kidney injury (AKI) risk following sodium-glucose 
cotransporter-2 (SGLT2) inhibitor use. This population-based retrospective cohort study 
in Ontario, Canada quantified the 90-day AKI risk in older adults who were newly 
dispensed either SGLT2 inhibitors or dipeptidyl peptidase-4 (DPP4) inhibitors in an 
outpatient setting between 2015 and 2017. Risk ratios (RR) were obtained using modified 
Poisson regression and risk differences using binomial regression. Relative to new use of 
a DPP4 inhibitor, initiation of an SGLT2 inhibitor was associated with a lower 90-day 
risk of a hospital encounter with AKI: 216 events in 19,611 patients (1.10%) versus 388 
events in 19,483 patients (1.99%); weighted RR 0.79 (95% confidence interval 0.64 to 
0.98). In routine care of older adults, new SGLT2 inhibitor use was associated with lower 
risk of AKI. Together with previous evidence, these findings suggest that regulatory 
warnings about AKI risk with SGLT2 inhibitors may be unwarranted. 
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Summary for Lay Audience 
The number of drugs used to treat patients with diabetes has grown significantly. 
Sodium-glucose costransporter-2 (SGLT2) inhibitors are an example of a new class of 
diabetes medications that help lower blood sugar by promoting its loss in the urine. 
Despite the ability of SGLT2 inhibitors to lower blood sugar, the US Food and Drug 
Administration (FDA) and Health Canada have issued safety warnings of the link 
between SGLT2 inhibitors and kidney injury. These warnings were made based on 
individual case reports and case series. We used health administrative databases to 
examine elderly patients with diabetes who were prescribed SGLT2 inhibitors and we 
examined kidney injury. We found that, in the first 90 days after being prescribed an 
SGLT2 inhibitor, patients had lower risk of developing kidney injury, compared to a 
similar group of people taking different diabetes medications. We suggest that the safety 
warnings and concerns about SGLT2 inhibitors and the risk of kidney injury might be 
revisited.  
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Chapter 1  
1 Introduction 
Sodium-glucose cotransporter-2 (SGLT2) inhibitors (e.g. canagliflozin, empagliflozin 
and dapagliflozin) are a class of diabetes medications used to treat type 2 disease. 
Although only newly available in Ontario since 2015 (1,2), their popularity is growing: in 
2016, an estimated 2 million prescriptions for SGLT2 inhibitors were filled in Canada 
alone (3). In addition to effectively lowering blood glucose levels, SGLT2 inhibitors are 
only one of two new diabetes therapy drug classes with evidence of cardiovascular risk 
reduction in patients with diabetes (4–7). 
SGLT2 inhibitors have however been linked with adverse outcomes. In October 2015 and 
June 2016 Health Canada and the United States Food and Drug Administration (FDA) 
issued safety warnings about the risk of acute kidney injury (AKI) after initiation of 
canagliflozin and dapagliflozin, based on case reports and case series (summarized in 
Appendix A) (8,9). These safety warnings led to changes in the drug product monographs 
to include information about the risk of AKI shortly after initiation. 
There is a plausible mechanism for SGLT2 inhibitor-induced AKI. By interfering with 
the co-uptake of glucose and sodium in the proximal nephron, SGLT2 inhibitors can 
increase sodium delivery to the distal nephron, which can result in afferent arteriole 
vasoconstriction and an associated reduction in estimated glomerular filtration rate 
(eGFR) (10–14). Even so, recent clinical trials and population-based studies suggest 
either no increase or a decrease in AKI risk after SGLT2 inhibitor initiation (4–7,10,15–
17). 
We conducted a population-based cohort study of older adults with diabetes newly 
dispensed an SGLT2 inhibitor or a dipeptidyl peptidase-4 (DPP4) inhibitor (a comparator 
drug also used to manage diabetes) in an outpatient setting. We conducted this study to 
better understand the association between SGLT2 inhibitor use and the 90-day risk of a 
hospital encounter (emergency department (ED) visit or hospital admission) for AKI in 
routine clinical practice.  
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Chapter 2  
2 Literature Review 
 
2.1 Diabetes burden and SGLT2 inhibitor prescribing 
According to the Canadian Chronic Disease Surveillance System, approximately 3 
million Canadians were living with diagnosed diabetes in 2014 (18). Patients with 
diabetes are at risk of a number of complications including cardiovascular disease, end-
stage renal disease (ESRD) and lower-limb amputations (19), and they face increased 
mortality (20,21). Patients with diabetes also incur high health care costs. (Rosella et al. 
showed that patients with diabetes cost the Canadian healthcare system about $16,000, 
compared with people without diabetes costing the healthcare system $6,000, over an 
eight-year period (22)). 
Over the last several years, there have been a number of drugs developed to reduce blood 
sugars and diabetes related complications. SGLT2 inhibitors including canagliflozin, 
empagliflozin and dapagliflozin have been available on the Ontario Drug Benefits 
Formulary since 2015 and 2016 (2). Standard daily drug doses for each of these drugs are 
listed in Appendix B. These drugs are also available as combination pills with other oral 
hypoglycemic medications (2). In 2016, an estimated 2 million prescriptions for SGLT2 
inhibitors were filled in Canada alone, as well as 4.4 million prescriptions in the United 
States (3,23).  
2.2 Mechanism of SGLT2 inhibitor glucose lowering 
SGLT2 inhibitors inhibit sodium-glucose cotransporters, located in the proximal 
convoluted tubule of the kidney nephron, from reabsorbing glucose into the bloodstream 
(24). Inhibition of sodium-glucose cotransporters causes higher urinary concentrations of 
glucose, and can lower the concentration of serum glucose (25). 
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2.3 SGLT2 inhibitors and the kidneys  
Acute kidney injury (AKI) is a serious condition characterized by a sudden increase in 
the concentration of serum creatinine (SCr) and a decrease in urine output (26). AKI 
ranges in severity. According to the 2012 Kidney Disease: Improving Global Outcomes 
(KDIGO) Clinical Practice Guideline, AKI can be diagnosed if any of the following 
criteria is met: (i) an increase in SCr ≥ 0.3 mg/dl (≥ 26.5 μmol/l within 48 hours; or (ii) an 
increase in SCr to ≥ 1.5 times a baseline measurement within 7 days; or (iii) a reduction 
in urine output < 0.5 ml/kg/h for 6 hours (27). 
According to the International Society of Nephrology, there are more than 13 million 
cases of AKI ever year (28). The presence of type 2 diabetes increases the risk of AKI 
(29,30). In addition, elderly patients are more likely to present with AKI (31,32), AKI is 
associated with a higher risk of all-cause mortality and ESRD, and higher healthcare 
costs (31,33,34). Therefore efforts to lower the risk of AKI in type 2 diabetes is vital.  
The mechanism of AKI following the use of an SGLT2 inhibitor is not entirely 
understood with a number of mechanisms proposed (35–37). Heerspink et al. suggest that 
by interfering with the co-uptake of glucose and sodium in the proximal nephron, SGLT2 
inhibitors can increase sodium delivery to the distal nephron, which can result in afferent 
arteriole vasoconstriction and an associated reduction in eGFR (10–14).  
There are several proposed mechanisms to explain a potential protective effect of SGLT2 
inhibitors and the risk of acute and chronic renal adverse events. Through their 
mechanism of action of decreasing glucose reabsorption at the kidneys, SGLT2 inhibitors 
may suppress renal swelling (38,39), inflammation (40) and may also affect energy 
metabolism in renal cells to improve efficiency (41). Since SGLT2 inhibitors also 
facilitate lower sodium reabsorption at the kidneys, these drugs can have beneficial 
effects that potentially may involve restoring tubuloglomerular feedback, oxygen 
consumption changes and improving renal anemia (42). Lastly, the beneficial systemic 
effects of SGLT2 inhibitors, such as reductions in body weight, blood pressure and 
insulin levels, can lead to renal protection. A reduction in body weight can lower 
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albuminuria and reduced insulin levels can lower the risk of hyperinsulinemia which can 
damage the kidneys (42,43).  
2.4 Search strategy and quality assessment of prior studies  
We conducted a literature review to identify prior studies that examined the association 
between SGLT2 inhibitor use and AKI. Both MEDLINE (1946 to July 2019) and 
EMBASE (1947 to July 2019) were searched, along with the first 5 pages of Google, in 
order to review the grey literature. For both databases, the final search strategy consisted 
of keywords such as acute kidney injury, acute kidney failure and sodium glucose 
cotransporter 2 inhibitor. Full information about the literature search strategies can be 
found in Appendix C.  
Inclusion and exclusion criteria were developed a priori. Studies were included if they 
met the following criteria: (i) full-text English article, (ii) randomized controlled trial 
(RCT) or cohort study, (iii) more than 1,000 patients, (iv) reported AKI as an outcome 
(AKI could be assessed in any manner such as diagnostic codes for an adverse event or 
actual SCr laboratory values). Studies were not included if they (i) were cross-sectional, 
commentaries, editorials, letters, methodology papers, or narrative review articles, (ii) 
had a sample size that was less than 1,000 patients, and (iii) did not report the outcome of 
AKI.  
2.5 Summary of previous literature 
Seven studies were identified as meeting our inclusion criteria. Four of these studies were 
RCTs and three were cohort studies. Overall, studies showed no risk or a reduction in 
both the acute and chronic renal adverse events amongst SGLT2 inhibitor users 
(summarized in Table 1). Our assessment of study quality using the Modified Downs and 
Black quality checklist (44) determined that three were of fair quality (16,16,18), one was 
of good quality (25), and three were of excellent quality (27,28,28).  
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2.6 SGLT2 inhibitors and acute kidney injury  
Two RCTs included in this literature review specifically intended to primarily assess 
efficacy in terms of renal outcomes associated with SGLT2 inhibitor use: CANVAS-R 
and the CREDENCE trial (5,7). The CREDENCE trial, published earlier this year, had a 
primary renal outcome and found that a safety endpoint of AKI was non-significantly 
lower in the arm randomized to canagliflozin compared with placebo (hazard ratio (HR) 
0.85 (95% CI 0.64-1.13)). The primary composite renal outcome of doubling of SCr, 
ESRD, renal death, and cardiovascular death occurred less frequently among patients 
randomized to canagliflozin versus placebo (HR 0.70 (95% CI 0.59-0.82)).  
Every study included in the literature review consistently showed that there was no 
increased risk of AKI amongst SGLT2 inhibitor users. However, all four of the major 
RCTs included in our review showed an initial drop in eGFR within 3 months of the 
initiation of an SGLT2 inhibitor (4–7,10). This drop in eGFR suggests a hemodynamic 
effect similar to the one observed following the initiation of angiotensin-converting–
enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) (45,46). This initial 
drop was reported to be reversible. 
 Additionally, case reports identified through the FDA adverse event reporting system 
database identified a signal of AKI following SGLT2 inhibitor use (47).
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Table 1. Literature review of 7 published studies describing adverse renal events associated with SGLT2 inhibitor use compared with 
other classes of hypoglycemic medications or hypoglycemic medication non-use for the treatment of hyperglycemia 
 
Author Study Description Results 
Study 
Limitations 
Study 
Procedure/Exposure 
Time 
Quality 
Scoreb 
Randomized Controlled Trials  
Zinman 
et al., 
2015 (4) 
- The EMPA-REG 
OUTCOME trial consisted 
of 7,020 patients at 590 
sites in 42 countries 
- Adult patients ≥18 years 
of age with type 2 diabetes 
and established 
cardiovascular disease were 
randomized to receive 
placebo, 10 mg of 
empagliflozin or 25 mg of 
empagliflozin  
- 2,333 patients received 
placebo and 4,687 patients 
received empagliflozin 
(mean age 63 years in both 
groups) 
- Early worsening of eGFR 
by about 3 ml/min/1.73m2 
within the first 12 weeks, 
but sustained function over 
time (10)a 
- The percentage of 
patients with AKI was 
lower in the empagliflozin 
groups compared to 
placebo 
- Doubling of the SCr 
level occurred less among 
empagliflozin users [HR 
0.56 (95% CI 0.39–0.79)] 
(10)a 
- The risk of renal-
- Renal findings 
may not be 
generalizable to 
patients without 
established 
cardiovascular 
disease  
- Kidney 
endpoints were 
exploratory (AKI 
was not one of 
the primary 
outcomes of 
interest) 
- Patients underwent a 2 
week, open-label, placebo 
run-in period  
- Patients either took 
empagliflozin or placebo 
once daily for a median 
duration of treatment of 2.6 
years 
- Additional follow-up visit 
30 days after the end of 
treatment 
- The median observation 
time was 3.1 years 
28 
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replacement therapy was 
lower amongst 
empagliflozin users [HR 
0.45 (95% CI 0.21-0.97)] 
(10)a 
Neal et 
al., 2017 
(5) 
- The CANVAS program 
consisted of integrated data 
from two trials (CANVAS 
& CANVAS-R) involving 
10,142 participants from 
667 centers in 30 countries 
- Adult patients ≥30 years 
of age with type 2 diabetes 
and high cardiovascular 
risk were randomized to 
receive placebo, 100 mg 
canagliflozin or 300 mg of 
canagliflozin in CANVAS; 
placebo, 100 mg of 
canagliflozin with an 
option to increase to 300 
mg of canagliflozin starting 
at week 13 in CANVAS-R  
- 4,347 patients received 
placebo and 5,795 patients 
received canagliflozin 
(mean age of 63 years in 
both groups) 
- No higher risk of AKI 
following canagliflozin 
use versus placebo 
- The composite outcome 
of a sustained 40% 
reduction in the estimated 
glomerular filtration rate, 
the need for renal-
replacement therapy, or 
death from renal causes 
occurred less frequently in 
patients receiving 
canagliflozin [HR 0.60 
(95% CI 0.47 to 0.77)] 
- Moderate 
number of events 
for important 
outcomes 
- AKI was not 
one of the 
primary 
outcomes of 
interest 
- Patients underwent a 2-
week, single-blind, placebo 
run-in period 
- The median follow-up 
was 126.1 weeks  
-71.4% of CANVAS-R 
patients in the canagliflozin 
treatment group had the 
dose increased to 300mg 
- The urinary ACR was 
measured every 26 weeks 
in CANVAS-R and at 
week 12 and annually 
thereafter in CANVAS 
- SCr with eGFR 
measurements were 
performed at least every 26 
weeks in both trials 
27 
Wiviott 
et al., 
2018 (6) 
- The DECLARE–TIMI 58 
trial consisted of 17,160 
participants at 882 sites in 
33 countries 
- Adult patients ≥40 years 
of age with type 2 diabetes 
and who had or were at risk 
- 8,578 patients received 
placebo and 8,582 patients 
received dapagliflozin 
(mean age 64 years in both 
groups) 
- AKI occurred less 
frequently in the 
- Renal findings 
may not be 
generalizable to 
patients not at 
risk for 
atherosclerotic 
cardiovascular 
- Patients underwent a 4-
to-8-week, single-blind 
run-in period during which 
they received placebo, and 
blood and urine testing was 
performed 
- Patients returned for 
28 
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for atherosclerotic 
cardiovascular disease were 
randomized to receive 10 
mg of dapagliflozin or 
matching placebo  
dapagliflozin group 
compared with placebo 
[HR 0.69 (95% CI 0.55 to 
0.87)] 
- The renal composite 
outcome of a sustained 
decrease of 40% or more 
in estimated glomerular 
filtration rate (eGFR), new 
ESRD, or death from renal 
or cardiovascular causes 
occurred less frequently in 
dapagliflozin users [HR 
0.76 (95% CI 0.67 to 
0.87)] 
disease 
- AKI was not 
one of the 
primary 
outcomes of 
interest 
 
follow-up every 6 months 
- Patients were contacted 
by telephone every 3 
months between in-person 
visits 
- Median follow-up time 
was 4.2 years 
Perkovic 
et al., 
2019 (7) 
- The CREDENCE trial 
consisted of 4,401 
participants with type 2 
diabetes and albuminuric 
chronic kidney disease  
- Adult patients ≥30 years 
of age were randomized to 
receive 100 mg of 
canagliflozin or matching 
placebo  
- 2,199 patients received 
placebo and 2,202 patients 
received canagliflozin 
(mean age 63 years in both 
groups) 
- Initial decline in eGFR 
within the first 3 months 
of initiation of 
canagliflozin  
- There was no difference 
in the risk of AKI between 
groups [HR 0.85 (95% CI 
0.64 to 1.13)] 
- The primary composite 
outcome of ESRD 
(dialysis, transplantation, 
- Findings about 
AKI may not be 
generalizable to 
those without 
established 
albuminuric 
chronic kidney 
disease  
- Trial was 
stopped early 
which might have 
limited the power 
for the AKI 
outcome 
 
- Patients underwent a 2-
week, single-blind, placebo 
run-in period  
- Patients were required to 
be receiving a stable dose 
of an ACE inhibitor or 
ARB for at least 4 weeks 
before randomization 
- Patients received 100mg 
once daily of canagliflozin 
or matching placebo with 
the use of randomly 
permuted blocks, with 
stratification according to 
the category of eGFR at 
screening 
25 
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or a sustained eGFR of 
<15 ml per minute per 
1.73 m2), a doubling of the 
SCr level, or death from 
renal or cardiovascular 
cause occurred less 
frequently among 
canagliflozin users [HR 
0.70 (95% CI 0.59 to 
0.82)] 
- Follow-up occurred at 
weeks 3, 13, and 26 and 
then alternated between 
telephone calls and in-
clinic visits at 13-week 
intervals 
- Median follow-up time of 
2.62 years 
Population-Based Studies  
Nadkarni 
et al., 
2017 (15) 
- Retrospective cohort 
study using data from the 
Mount Sinai chronic kidney 
disease registry, between 
January 2014 and 
December 2016, and the 
Geisinger Health System 
cohort, between January 
2013 and February 2017, in 
the United States, to 
compare SGLT2 inhibitor 
users versus nonusers 
- Mount Sinai cohort 
(mean age 63 years) - 
SGLT2 inhibitor users: 
n=372; nonusers: n=372 
- Geisinger cohort (mean 
age 58 years) - SGLT2 
inhibitor users: n=1,207; 
nonusers: n=1,207 
- In the Mount Sinai 
cohort, the adjusted 
hazards of AKIKDIGO were 
60% lower in SGLT2 
inhibitor users compared 
to nonusers [adjusted HR 
0.40 (95% CI 0.20 to 
0.70)] 
- In the Geisinger cohort, 
the adjusted hazards of 
AKIKDIGO was not 
- In the Mount 
Sinai cohort, 
users and 
nonusers were 
not well matched 
on race, HbA1c 
levels, thiazide 
diuretics, and 
metformin use 
- Urine ACR 
measurements 
were missing in 
85% of the 
Mount Sinai 
cohort 
- Residual 
confounding and 
confounding by 
indication may 
- Only patients with type 2 
diabetes and available SCr 
measurements were 
included 
- Exposure was a new 
prescription for 
canagliflozin, 
empagliflozin or 
dapagliflozin 
- Follow-up time was 
similar in SGLT2 inhibitor 
users and nonusers (458 vs. 
439 days) 
16 
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different between SGLT2 
inhibitor users and 
nonusers [adjusted HR 
0.60 (95% CI 0.40 to 
1.10)] 
likely be present  
Cahn et 
al., 2018 
(16) 
- Retrospective cohort 
study using claims data 
from Israel to compare 
patients initiated on an 
SGLT2 inhibitor or DPP4 
inhibitor between April 
2015 to June 2017 
- SGLT2 inhibitor users: 
n=6,418 (mean age 62 
years); DPP4 inhibitor 
users: n=5,604 (mean age 
64 years) 
- The risk of AKI [OR 
0.47 (95% CI 0.27 to 
0.80)] was lower in 
patients initiating an 
SGLT2 inhibitor versus a 
DPP4 inhibitor 
- May be 
selection bias in 
patients who 
initiated an 
SGLT2 inhibitor 
or DPP4 inhibitor  
- Since 
canagliflozin is 
not available in 
Israel, only 
patients who 
initiated 
empagliflozin or 
dapagliflozin 
were included  
- Residual 
confounding may 
be present 
 
- Only dapagliflozin and 
empagliflozin are available 
in Israel  
- The index date was 
defined as the first date of 
purchase of SGLT2 
inhibitor or DPP4 inhibitor 
- At least two consecutive 
prescriptions within 120 
days on the index date was 
required for study inclusion 
- The first SCr 
measurement within 2 to 
24 weeks after index was 
defined as the follow-up 
measurement 
- Follow-up time was 24 
weeks following the index 
date 
16 
Ueda et 
al., 2018 
(17) 
- Retrospective cohort 
study using data from 
nationwide health and 
administrative registers in 
Sweden and Denmark to 
compare patients that 
newly initiated an SGLT2 
- SGLT2 inhibitor users: 
n=17,213; GLP1 receptor 
agonists: n=17,213 (mean 
age 61 years after 
matching) 
- No increase in the risk of 
AKI [HR 0.69 (95%CI 
- The use of 
canagliflozin was 
rare among 
SGLT2 inhibitor 
users 
- Medication 
compliance might 
- The date of filling the 
first new prescription was 
considered the index date 
- Patients were classified as 
exposed if prescriptions 
were refilled before the 
estimated end date of the 
18 
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inhibitor or a GLP1 
receptor agonist between 
July 2013 to December 
2016 
0.45 to 1.05)] in SGLT2 
inhibitor users compared 
to GLP1 receptor agonist 
users 
bias the results of 
this study 
towards the null 
- The codes for 
AKI have not 
been validated 
which may have 
led to outcome 
misclassification 
- Residual 
confounding may 
be present 
 
most recent prescription 
- Median follow-up time 
ranged between 270 and 
274 days 
 
Abbreviations: ACE= angiotensin-converting–enzyme, ACR= albumin-to-creatinine ratio, AKI= acute kidney injury, ARB= 
angiotensin-receptor blocker, CI= confidence interval, DPP4= dipeptidyl peptidase-4, eGFR = estimated glomerular filtration rate, 
ESRD= end-stage renal disease, GLP1= glucagon-like peptide-1, HbA1c= glycated hemoglobin, HR= hazard ratio, KDIGO= kidney 
disease improving global outcomes, OR= odds ratio, SCr= serum creatinine, SGLT2= sodium-glucose cotransporter-2 
aWanner et al. presented the results of a prespecified secondary objective of the EMPAREG-OUTCOME trial, which was to examine 
the effects of empagliflozin on microvascular outcomes.  
bWe evaluated the quality of studies using the Modified Downs and Black checklist for the assessment of the methodological quality 
of both randomized and non-randomized studies. We gave all studies a score from 0 to 27, grouped into the following four quality 
levels: excellent (26 to 28), good (20-25), fair (15-19) and poor (14 or less). 
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Chapter 3  
3 Rationale and Research Questions 
 
3.1 The need for research  
Many previous studies exploring the link between SGLT2 inhibitors and AKI have been 
RCTs and may not represent routine clinical practice. In the real-world, for example, 
patients in routine clinical practice are generally monitored less often and have more 
comorbidity than patients in clinical trials (48). There may also be low rates of AKI 
among patients well-managed in a trial setting who receive regimented safety monitoring 
that is not attainable in real-world clinical practice. This may result in a potential 
underestimate of relative and absolute safety, as has been observed with limb amputation 
in some studies (17,49). In addition, in the real-world, clinicians are increasingly 
educated on appropriate SGLT2 inhibitor use in routine clinical practice which includes 
counseling patients not to take the drug during an acute illness (50). We conducted this 
study to better understand the association between SGLT2 inhibitor use and the 90-day 
risk of a hospital encounter (ED visit or hospital admission) for AKI in routine clinical 
practice.  
 
3.2 Research questions and hypothesis  
3.2.1 Primary Research Question 
Does a group of older adults with diabetes newly dispensed SGLT2 inhibitors compared 
with a group of patients newly dispensed DPP4 inhibitors, who have similar indicators of 
baseline health, have an altered 90-day risk of a hospital encounter with AKI? 
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3.2.2 Secondary Research Questions 
1) Does a group of older adults with diabetes newly dispensed SGLT2 inhibitors 
compared with a group of patients newly dispensed DPP4 inhibitors, who have 
similar indicators of baseline health, have an altered 90-day risk of hospitalization 
with AKI? 
 
2) Does a group of older adults with diabetes newly dispensedSGLT2 inhibitors 
compared with a group of patients newly dispensed DPP4 inhibitors, who have 
similar indicators of baseline health, have an altered 90-day risk of a hospital 
encounter with moderate to severe AKI? 
 
3) Does a group of older adults with diabetes newly dispensed SGLT2 inhibitors 
compared with a group of patients newly dispensed DPP4 inhibitors, who have 
similar indicators of baseline health, have an altered 90-day risk of AKI restricted to 
the outpatient setting? 
 
4) Does a group of older adults with diabetes newly dispensed SGLT2 inhibitors 
compared with a group of patients dispensed DPP4 inhibitors, who have similar 
indicators of baseline health, have an altered 90-day risk of AKI in all settings 
(outpatient, emergency room, in-patient hospitalization)? 
 
Regulatory warnings and recent literature are conflicting, as the warnings describe a 
higher risk of AKI after SGLT2 inhibitor initiation, but recent literature showed no 
difference in risk or lower risk of AKI after SGLT2 inhibitor initiation. Therefore, we are 
uncertain of the direction of association between SGLT2 inhibitor initiation and the risk 
of AKI. 
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Chapter 4  
4 Methods 
4.1 Study design and setting 
We conducted a population-based retrospective cohort study of older adults aged ≥66 
years in Ontario between July 1, 2015 and September 30, 2017 using linked healthcare 
databases in Ontario, Canada. Ontario has >14 million residents, 17% of whom are aged 
65 years or older (51). Ontario residents are covered by publicly-funded, universal health 
insurance. The Ontario Health Insurance Plan (OHIP) covers physician and hospital 
services for all Ontario residents. Those aged 65 years and older receive prescription drug 
coverage through the Ontario Drug Benefit (ODB) program. Dispensation records for 
individuals not covered by the ODB program are not available. 
Health administrative databases are increasingly being used for population-based studies 
(52). Administrative database studies allow investigators to study large samples of 
patients for long follow-up periods and examine outcomes in a routine-care setting. In 
addition, loss to follow-up is of little concern since emigration from Ontario is less than 
0.1% annually (53). We have successfully used these data sources to study associations 
between a number of drugs and risk of AKI (54–57).  
We conducted this study at ICES, a not-for-profit research institute within Ontario. The 
use of data in this project was authorized under section 45 of Ontario’s Personal Health 
Information Protection Act, which does not require review by a Research Ethics Board. 
We followed reporting guidelines for observational pharmacoepidemiology studies 
(Appendix D) (58). 
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4.2 Databases 
We used nine health administrative databases to ascertain patient information, drug 
exposure status, covariate and outcome information. Databases were linked using unique 
encoded identifiers and analyzed at ICES. We have used a number of these databases in 
previous pharmacoepidemiologic studies (55–57,59–62). 
Ontario Drug Benefit (ODB) Database: The ODB database contains prescription claims 
data for individuals aged 65 years or older covered through the ODB Program. This 
database was used to ascertain SGLT2 inhibitor or DPP4 inhibitor exposure status as well 
as baseline drug use prior to the cohort entry date. We also acquired patient residential 
status to remove long-term care residents from our cohort.  
Registered Persons Database of Ontario (RPDB): We used this database to acquire 
information on patient demographics (age and sex), as well as income quintiles (based on 
neighborhood average incomes), and residence location (urban or rural).  
ICES Physician Database (IPDB): The IPDB contains information about all physicians in 
Ontario, including demographics, specialty, and measures of physician activity (billings 
and workload data). We used this database to acquire information about the prescribing 
physician’s specialty. We also determined the specialty of the physician for the baseline 
number of general physician visits, cardiologist, ophthalmologist, endocrinologist and 
nephrologist consults.  
Canadian Institute for Health Information (CIHI) Discharge Abstract Database (DAD), 
National Ambulatory Care Reporting System (NACRS) and Same Day Surgery (SDS) 
Database: CIHI-DAD contains patient-level information on hospitalizations in Ontario. 
The NACRS database captures information on patient visits to hospital emergency 
departments or other community-based ambulatory care clinics. The SDS dataset 
contains patient-level data for day surgery institutions in Ontario. Diagnostic codes are 
entered into these databases including the International Classification of Diseases, Tenth 
Revision (ICD-10) codes. We used these databases to ascertain baseline comorbidities in 
the 5 years prior to the cohort entry date, as well as the number of hospitalizations and 
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ED visits. We used ICD-10 codes to ascertain our primary outcome of a hospital 
encounter with AKI.  
Ontario Health Insurance Plan (OHIP) Claims Database: The OHIP Claims Database 
contains information on health care providers’ billing claims for inpatient and outpatient 
services in Ontario, as well as associated diagnoses. We used this data source to ascertain 
whether patients received dialysis in the one year prior to the cohort entry date (exclusion 
criteria). We also gathered additional information on baseline comorbidities and 
healthcare utilization. Further, we used OHIP billing codes in outcome ascertainment to 
collect information about acute dialysis.  
Ontario Laboratories Information System (OLIS): OLIS is an electronic repository that 
houses laboratory test results beginning in 2007 in hospitals and community laboratories 
across the province. Since not all laboratories began submitting their data to OLIS 
simultaneously, we identified geographical areas across Ontario where residents would 
likely visit a hospital with linked laboratory data (referred to as the laboratory catchment 
area). We included only Ontarians that resided within these laboratory catchment areas. 
We used information from OLIS to determine baseline SCr measurements, other baseline 
laboratory measurements as well as inpatient and outpatient laboratory data for our 
outcomes.  
Ontario Diabetes Dataset (ODD): The ODD contains all individuals within Ontario with 
any type of non-gestational diabetes. We used this data source to determine duration of 
diabetes for all individuals in our cohort.  
 
4.3 Patients 
We created a cohort of older adults aged ≥66 years in Ontario who were newly dispensed 
an SGLT2 inhibitor (canagliflozin, empagliflozin or dapagliflozin) or a DPP4 inhibitor 
(saxagliptin, sitagliptin or linagliptin) between July 1, 2015 (the earliest date of SGLT2 
inhibitor coverage by ODB) (2) and September 30, 2017. We chose DPP4 inhibitors as 
our comparator as they are also a second to third line medication for diabetes (reduces 
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concerns of confounding by indication) and unlike SGLT2 inhibitors, have no known risk 
of AKI (63,64). The dispensing date of their first eligible prescription during the accrual 
period was considered the cohort entry or index date. We limited our cohort to those aged 
≥66 years to establish complete medication history and ensure they were not in their first 
eligibility year for prescription drug coverage (age 65 years), and to those who fell in 
OLIS catchment areas, using previously published methods (65). We included only 
Ontarians who resided within these catchment areas to ensure accurate outcome 
ascertainment, as not all hospital-based laboratories started contributing to OLIS at the 
same time, and to date, not all contribute. In order to accurately ascertain outcomes for 
individuals in our cohort, we ensured individuals resided within areas serviced by OLIS, 
so that they would be receiving SCr tests in hospitals captured in our data sources. We 
assessed eGFR using the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation (66). Patients were included if their corresponding baseline eGFR value 
was above 45 mL/min per 1.73 m2, as SGLT2 inhibitors were contraindicated in Ontario 
for patients with a lower eGFR during the study period (67). Lastly, to define new use, 
we required that patients be free of the study drugs for at least 180 days prior to the index 
date and studied the first such exposure during accrual period. 
We excluded: (i) those with a prescription for more than one type of DPP4 inhibitor or 
SGLT2 inhibitor on the index date to compare mutually exclusive groups; (ii) those 
residing in long-term care since these individuals are inherently different than the general 
population in terms of disease and medication management (68); (iii) those discharged 
from a hospital in the two days prior to the index date, to ensure new outpatient 
prescriptions since patients who initiate treatment in hospital typically fill ongoing 
prescriptions on the discharge date or the day after; and (iv) individuals with non-
standard daily drug doses for diabetes treatment to ensure applicability to usual 
prescribing (5mg/day to 300mg/day depending on the drug) (Appendix B) (69). Finally, 
for patients with multiple eligible prescriptions we restricted to the first eligible one.  
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4.4 Baseline characteristics 
We assessed baseline comorbidities in the five years prior to the cohort entry date (except 
the Charlson comorbidity index which had a 2-year look back period) and medication use 
in the 120 days prior to the cohort entry date. Dispensing of other hypoglycemic 
medications was examined in the 120 days prior to the cohort entry date, on the cohort 
entry date and in the one year to 120 days prior to the cohort entry date. Health care 
utilization was assessed in the year prior to the cohort entry date, except for bone mineral 
density tests, hearing tests, sputum tests, which were all assessed in the 5 years prior to 
the cohort entry date. Additionally, wound swabs were measured in the 7 days prior to 
the cohort entry date, and electroencephalography in the 90 days prior to the cohort entry 
date. We assessed baseline kidney function using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation (66) and baseline SCr measurements 
for the entire cohort, in the one year prior to the cohort entry date. We had no information 
about race and assumed all patients to be nonblack for the CKD-EPI equation (<5% of 
the Ontario population is of black race) (70). For individuals with laboratory data 
available, we also captured serum potassium values, albumin-to-creatinine (ACR) ratio 
measurements and glycated hemoglobin (HbA1c) in the one year prior to the cohort entry 
date (see Appendix E for all coding definitions). 
 
4.5 Inverse probability of treatment weighting 
We used inverse probability of treatment weighting (IPTW) based on propensity scores to 
minimize the systematic differences in the measured baseline characteristics of our 
SGLT2 and DPP4 groups. By using weights based on propensity scores, we created a 
synthetic population where the distribution of baseline characteristics was independent of 
their drug exposure status, while retaining data from all included individuals (71).  
To do this, we estimated the propensity scores using a multivariable logistic regression 
model with 97 baseline characteristics (selected because of their association with both the 
outcome of AKI and type of oral hypoglycemic agent dispensed (see Appendix F for 
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variables included in the propensity score). We then used weights to estimate the average 
treatment effect in the treated (ATT), where SGLT2 inhibitors were considered the 
treated population (72). Patients in the reference group were weighted as [propensity 
score/(1 - propensity score)], while patients in the exposed group received a weight of 1. 
This allowed us to create a weighted pseudo-sample of patients in the reference group 
with the same distribution of measured covariates as the exposure group (71,73,74). 
The 97 variables used to estimate propensity scores were complete, except for prescriber 
specialty (<10% missing), rural residence (<0.5% missing) and neighbourhood income 
quintile (<0.5% missing). Prior to weighting, we classified missing prescriber specialty as 
a ‘missing’ category, missing rural status as non-rural, and imputed the third income 
quintile for missing income status. Emigration from Ontario is less than 0.1% per year 
and was the only reason for lost follow-up (53). 
 
4.6 Outcomes 
4.6.1 Primary outcome  
Our primary outcome was a hospital encounter (hospitalization or ED presentation) with 
AKI, defined by 2012 KDIGO thresholds: ≥50% increase in SCr concentration over 
baseline, or an absolute increase of at least 27 µmol/L (0.3 mg/dL) or receipt of dialysis 
for AKI (27). The baseline value was the most recent outpatient SCr value within the past 
year. We compared this baseline value to the highest hospital-based SCr value in the 90 
days following cohort entry. We chose a 90-day follow-up period based on prior evidence 
showing that SGLT2 inhibitors lead to an eGFR decline soon after drug initiation (7,10). 
4.6.2 Secondary outcomes  
As secondary outcomes, we assessed hospital admission with AKI, and hospital 
encounter with moderate to severe AKI (SCr increase meeting KDIGO threshold of stage 
2 or more AKI; defined in Appendix G) (27). We also examined evidence of AKI in the 
outpatient setting, and AKI in any setting (outpatient, in-hospital or ED).  
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4.7 Additional analyses 
We conducted six additional analyses to assess the robustness of our results.  
To assess the possibility of surveillance bias, we examined the proportion of patients in 
both groups who had at least one outpatient SCr measurement during the follow-up 
period. 
To complement analyses examining increases in SCr as a binary outcome, we assessed 
absolute and relative changes in SCr measurements after drug initiation.  
We completed sub-group analyses to understand potential SGLT2 inhibitor-associated 
risks in vulnerable segments of the population who are at higher risk of AKI (75–81). We 
examined the association between SGLT2 inhibitor use (versus DPP4 inhibitor use) and 
the primary outcome, stratified by presence or absence of four characteristics: (1) 
baseline eGFR <60 mL/min per 1.73 m2, (2) concurrent ACE inhibitor or ARB use, (3) 
concurrent diuretic use, and (4) age >80 years (Appendix H).  
We performed a survival analysis of the primary outcome within 365 days of follow-up, 
censoring on death.  
We evaluated the 90-day risk of a hospital encounter with bowel obstruction, as a 
negative control outcome which was not expected to be associated with SGLT2 inhibitor 
or DPP4 inhibitor use. 
We performed an E-value analysis in order to assess how robust our association was to 
potential unmeasured confounding (82). 
 
4.8 Statistical analyses 
We conducted all analyses using SAS version 9.4 (SAS Institute, Cary, NC, USA). DPP4 
inhibitors were the referent group for all analyses. Two-tailed P values less than 0.05 
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were considered statistically significant for all outcomes. We present the 95% confidence 
intervals (CIs) for all primary outcome estimates, which correspond to a level of 
significance of 0.05. In addition to statistical significance, clinical significance was also 
considered by including input from practicing physicians.  
We compared baseline characteristics between those newly dispensed SGLT2 inhibitors 
and DPP4 inhibitors using standardized differences, for which a threshold of ≥10% was 
considered meaningful (83). The standardized difference was chosen because it is less 
sensitive to sample size, in comparison to hypothesis testing (84), and has been 
previously used to compare the distribution of baseline characteristics between treatment 
groups (85–87). 
To estimate weighted risk ratios (RRs) and 95% CIs, we used a modified Poisson 
regression by specifying a generalized linear model assuming a Poisson distribution and 
log link function with a repeated statement to obtain robust error variances (88). The 
modified Poisson regression provides estimates of RR for dichotomous outcomes. The 
clinical interpretation of the RR has more value, when compared with the odds ratio (OR) 
(88–90). The modified Poisson regression was selected over other models that estimate 
the RR directly in order to avoid the common convergence issues encountered when 
using a log-binomial regression model and the conservative results produced from 
Poisson regression (91–97). To estimate weighted risk differences (RDs) between the 
groups and 95% CIs, we used binomial regression with an identity link function (92).  
To evaluate the effect of SGLT2 inhibitor use on AKI for specific subgroups, we first 
included an interaction term between our exposure and subgroup indicator in our 
modified Poisson model. This resulted in an interaction P value, which allowed us to 
assess departure from risk-ratio multiplicativity (98).  
To assess absolute and relative changes in SCr measurements after drug initiation, 
weighted mean differences and 95% CIs were obtained using an ordinary least squares 
linear regression model with an identity link function. This model was used because we 
were interested in comparing SCr measurements as a continuous variable (99).  
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To examine the primary outcome within 365 days of follow-up, we used Cause specific 
weighted Cox proportional hazards regression, censoring on the competing risk of death 
to estimate weighted HRs (99). The corresponding 95% CI was obtained using a 
bootstrap estimator (100). In addition, the proportional hazards assumption was tested by 
including time dependent covariates in the model and the assumption was not violated. 
To further explore the competing risk of death, we estimated the subdistributions hazards 
using a Fine and Gray model treating death as a competing risk (101). However, the 
applicability of this model when using IPTW has not yet been fully explored in the 
literature (102). As such, we included this analysis only to explore the potential impact of 
death in the estimation of AKI within 365 days in SGLT2 users compared to DPP4 users.  
In order to assess how robust our association was to potential unmeasured confounding, 
we performed an E-value analysis to obtain the minimum strength of association that a 
combination of unmeasured confounders would need to have with both the exposure and 
outcome to negate the observed results (82,103). The E-value is a measure of a given 
association’s robustness to potential unmeasured confounders (82). We produced a 
plotted curve using an online E-value calculator that provides the e-value for the point 
estimate of our primary outcome and for the CI of the primary outcome (104). However, 
in general with the E-value analysis, caution is warranted when interpreting the E-values 
as these values are a simplification of the context around the study (i.e. the exposure-
outcome association in question, how well all currently measured confounders were 
accounted for, etc.) (105).  
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Chapter 5  
5 Results 
 
5.1 Cohort characteristics  
5.1.1 Unweighted cohort 
After exclusions, we identified 19,611 patients newly dispensed an SGLT2 inhibitor and 
19,483 patients newly dispensed a DPP4 inhibitor between July 1, 2015 and September 
30, 2017 (see Figure 1 for cohort assembly). Baseline characteristics pre- and post-
weighting are presented in Table 2. The mean age of the unweighted cohort was 71 years 
for SGLT2 inhibitor users and 74 years for DPP4 inhibitor users. 48% of DPP4 inhibitor 
users and 40% of SGLT2 inhibitor users were women. A total of 48% of SGLT2 inhibitor 
users were dispensed canagliflozin, 37% empagliflozin and 15% dapagliflozin. The 
median (25th, 75th percentile) doses were 100 (100-300) mg/day for canagliflozin, 10 (10-
10) mg/day for empagliflozin, and 10 (5-10) mg/day for dapagliflozin.  
Prior to weighting, SGLT2 inhibitor users were more likely to be younger (71 vs. 74 
years), more likely to receive their prescription from an endocrinologist (19.3% vs. 
7.6%), were less likely to have a prior AKI diagnosis (1.8% vs. 3.6%), were more likely 
to be taking ACE inhibitors (36.5% vs. 31.5%) and were more likely to have HbA1c 
levels checked (96.9% vs. 94.4%) than DPP4 users (Table 2). Socioeconomic status was 
missing for 33 (0.2%) of SGLT2 inhibitor users and 18 (0.1%) of DPP4 inhibitor users. 
Residential information was not available for 33 (0.2%) SGLT2 inhibitor users and 18 
(0.1%) DPP4 inhibitor users. In addition, prescriber information was unavailable for 
1,261 (6.5%) of DPP4 inhibitor users and 1,091 (5.6%) of SGLT2 inhibitor users.  
5.1.2 Weighted cohort 
The mean age was 71 years and 40% were women for both SGLT2 inhibitor users and 
DPP4 inhibitor users. Baseline SCr was measured a median of 28 days (IQR 9-89) prior 
for SGLT2 inhibitor users and 23 (8-81) days for DPP4 inhibitor users. After weighting, 
24 
 
 
groups remained imbalanced on eGFR categories, but where considered as a continuous 
variable, there was no statistical or clinically meaningful difference between groups. 
Overall 17% of the cohort had a weighted baseline eGFR between 45 and 60 mL/min per 
1.73 m2.  
Over 120 measured baseline characteristics were similar between SGLT2 inhibitor users 
and DPP4 inhibitor users, including diabetes parameters, diabetes medications and 
healthcare utilization measures. Prescriber information was missing for 1,131 (5.7%) 
DPP4 inhibitor users and 1,091 (5.6%) of SGLT2 inhibitor users. General practitioners 
were the most frequent prescribers (65%) for both SGLT2 inhibitors and DPP4 inhibitors 
(Table 2). 
 
5.2 Main analysis 
5.2.1 Primary outcome 
Relative to new DPP4 inhibitor use, new SGLT2 inhibitor use was associated with a 
lower 90-day risk of a hospital encounter with AKI: 216 events in 19,611 patients 
(1.10%) versus 388 events in 19,483 patients (1.99%); weighted RR 0.79 (95% CI 0.64 to 
0.98), p-value 0.04; weighted RD -0.29% (95% CI -0.57% to -0.01%) (Table 3).  
5.2.1 Secondary outcomes 
SGLT2 inhibitor use was associated with a lower 90-day risk of hospitalization with 
AKI: 149 events in 19,611 patients (0.76%) versus 291 events in 19,483 patients 
(1.49%); weighted RR 0.73 (95% CI 0.56 to 0.95), p-value 0.02; weighted RD -0.28% 
(95% CI -0.53% to -0.03%) (Table 2). The point estimate for the risk of hospital 
encounter with moderate to severe AKI following SGLT2 inhibitor use compared with 
DPP4 inhibitor use was similar to the primary outcome analysis. However with fewer 
events, there was less precision in the estimate and the between-group difference was not 
significantly different: 44 events in 19,611 patients (0.22%) versus 74 events in 19,483 
patients (0.38%) events; weighted RR 0.81 (95% CI 0.49 to 1.33), p-value 0.40. There 
was no significant difference in the risk of AKI in an outpatient setting: 573 events in 
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19,611 patients (2.92%) versus 609 events in 19,483 patients (3.13%); weighted RR 1.13 
(95% CI 0.95 to 1.33), p-value 0.16 and AKI in all settings: 716 in 19,611 patients 
(3.65%) versus 837 events in 19,483 patients (4.30%) events; weighted RR 1.06 (95% CI 
0.92 to 1.22), p-value 0.42 (Table 3). 
 
5.3 Additional analyses 
Over a 90-day follow-up, SGLT2 inhibitor users were more likely to have at least one 
SCr measurement in the outpatient setting compared with DPP4 inhibitor users [10,619 
(54.2%) of SGLT2 inhibitor users and 9,602 (49.3%) of DPP4 inhibitor users, p-value < 
0.01 (Appendix I)]. 
The change in SCr concentration in follow-up compared to the baseline value for SGLT2 
inhibitor users and DPP4 inhibitor users is presented in Appendices J and K. SGLT2 
inhibitor users, compared with DPP4 inhibitor users, had a slightly greater change in SCr 
concentration from baseline during follow-up, however the change was not clinically 
significant [weighted mean between-group difference in absolute terms was 1 µmol/L 
(95% CI 0.3 to 1.7), p-value < 0.01; and as a percentage was 1.3% (95% CI 0.4 to 2.1), p-
value < 0.01].  
Baseline eGFR, ACE inhibitor or ARB use, diuretic use, and older age did not 
significantly modify the association between SGLT2 inhibitor (versus DPP4 inhibitor) 
use and the risk of AKI (P values for interaction ranged from 0.28-0.83) (Figure 2).  
Over a 365-day follow-up period, SGLT2 inhibitor use was associated with a lower risk 
of hospital encounter with AKI: 2,666 events in 19,611 patients (13.6%) versus 3,712 
events in 19,483 patients (19.1%), 172 versus 208 weighted events per 1,000 person-
years, respectively; HR 0.83 (95% CI 0.78 to 0.89) (Appendix L). A similar result was 
observed when death was treated as a competing risk.  
A significant difference in hospital encounters with bowel obstruction between SGLT2 
inhibitor users and DPP4 inhibitor users was neither expected nor observed: 20 events in 
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19,611 patients (0.10%) versus 36 events in 19,483 patients (0.18%); weighted RR 1.00 
(95% CI 0.49 to 2.06), p-value 1.00 (Appendix M). 
The E-values for the relative risk and lower confidence bound for the primary outcome 
were 1.83 and 1.14, respectively, indicating the amount of unmeasured confounding that 
would be needed to bias the observed association to the null (Appendix N). 
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Figure 1. Cohort assembly for patients in the SGLT2 inhibitor user group and the comparator DPP4 
inhibitor user group 
aESRD defined as evidence of previous dialysis or renal transplant; bTo ensure two mutually exclusive 
groups; cIndividuals are inherently different than the general population in terms of medication 
management; dTo ensure new outpatient prescriptions; eTo ensure applicability to usual prescribing 
 
  
 
  
28 
 
 
Table 2. Baseline characteristics of older adults with type 2 diabetes newly dispensed SGLT2 inhibitors (canagliflozin, dapagliflozin 
or empagliflozin) and DPP4 inhibitors (saxagliptin, sitagliptin or linagliptin) in Ontario, Canada (2015-2017) 
 
Characteristica 
Observed data   Weighted datab  
No. (%) of patients  No. (%) of patients   
SGLT2 
inhibitors  
(n = 19,611) 
DPP4 
inhibitors  
(n = 19,483) 
Standardized 
Differencec 
(%) 
SGLT2 
inhibitors  
(n = 19,611) 
DPP4 
inhibitors  
(n = 19,775) 
Standardized 
Differencec 
(%) 
SGLT2 inhibitor type  
Canagliflozin 9,404 (48.0)      
Empagliflozin 7,311 (37.3)      
Dapagliflozin 2,896 (14.8)      
DPP4 inhibitor type 
Sitagliptin  13,086 (67.2)     
Linagliptin  4,726 (24.3)     
Saxagliptin  1,671 (8.6)     
Demographics 
Age, year, mean ± SD  71.4 ± 4.86 74.1 ± 6.3 47 71.4 ± 4.9 71.4 ± 5.0 1 
Age, year, median 
(IQR) 
70 (68 to 74) 73 (69 to 78) 43 70 (68 to 74) 70 (68 to 74) 1 
  66-74 15,017 (76.6) 11,415 (58.6) 39 15,017 (76.6) 15,224 (77.0) 1 
  75-84 4,249 (21.7) 6,586 (33.8) 27 4,249 (21.7) 4,153 (21.0) 2 
  85+ 345 (1.8) 1,482 (7.6) 28 345 (1.8) 398 (2.0) 1 
Women 7,903 (40.3) 9,325 (47.9) 15 7,903 (40.3) 8,104 (41.0) 1 
Rural Residenced 2,192 (11.2) 2,088 (10.7) 2 2,192 (11.2) 2,423 (12.3) 3 
Year of cohort entry    
  2015 3,571 (18.2) 4,260 (21.9) 9 3,571 (18.2) 3,187 (16.1) 6 
  2016 8,060 (41.1) 9,153 (47.0) 12 8,060 (41.1) 8,940 (45.2) 8 
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  2017 7,980 (40.7) 6,070 (31.2) 20 7,980 (40.7) 7,647 (38.7) 4 
Neighbourhood income quintilee      
  1 (low) 4,350 (22.2) 4,566 (23.4) 3 4, 350 (22.2) 4,397 (22.2) 0 
  2 4236 (21.6) 4,390 (22.5) 2 4,236 (21.6) 4,328 (21.9) 1 
  3 4,011 (20.5) 3,953 (20.3) 0 4,044 (20.6) 4,047 (20.5) 0 
  4 3,679 (18.8) 3,513 (18.0) 2 3,679 (18.8) 3,683 (18.6) 1 
  5 (high) 3,302 (16.8) 3,043 (15.6) 3 3,302 (16.8) 3,321 (16.8) 0 
Local health integration network (LHIN) 
  1 36 (0.2) 15 (0.1) 3 36 (0.2) 29 (0.1) 3 
  2 1,765 (9.0) 1,890 (9.7) 2 1765 (9.0) 1,869 (9.4) 1 
  3 254 (1.3) 179 (0.9) 4 254 (1.3) 262 (1.3) 0 
  4 21 (0.1) 19 (0.1) 0 21 (0.1) 23 (0.1) 0 
  5 1,864 (9.5) 1,954 (10.0) 2 1,864 (9.5) 1,797 (9.1) 1 
  6 2,121 (10.8) 2,696 (13.8) 9 2,121 (10.8) 2,162 (10.9) 0 
  7 1,774 (9.0) 1,852 (9.5) 2 1,774 (9.0) 1,873 (9.5) 2 
  8 3,441 (17.5) 3,332 (17.1) 1 3,441 (17.5) 3,167 (16.0) 4 
  9 4,897 (25.0) 4,218 (21.6) 8 4,897 (25.0) 5,058 (25.6) 1 
  10 967 (4.9) 751 (3.9) 5 967 (4.9) 1,019 (5.2) 1 
  11 290 (1.5) 345 (1.8) 2 290 (1.5) 278 (1.4) 1 
  12 996 (5.1) 813 (4.2) 4 996 (5.1) 1,00 (5.1) 0 
  13 825 (4.2) 984 (5.1) 4 825 (4.2) 874 (4.4) 1 
  14 360 (1.8) 435 (2.2) 3 360 (1.8) 363 (1.8) 0 
Prescriber Speciality  
  Cardiologist 413 (2.1) 108 (0.6) 13 413 (2.1) 506 (2.6) 3 
  Endocrinologist 3,786 (19.3) 1,475 (7.6) 35 3,786 (19.3) 3,574 (18.1) 3 
  General practitioner  12,798 (65.3) 15,685 (80.5) 35 12,798 (65.3) 12,927 (65.4) 0 
  Internist 1,139 (5.8) 540 (2.8) 15 1,139 (5.8) 1,232 (6.2) 2 
  Nephrologist  217 (1.1) 97 (0.5) 7 217 (1.1) 234 (1.2) 1 
  Other 167 (0.9) 317 (1.6) 6 167 (0.9) 171 (0.9) 0 
  Missing 1,091 (5.6) 1,261 (6.5) 4 1,091 (5.6) 1,131 (5.7) 0 
Comorbidities in prior 5 years 
30 
 
 
Duration of diabetes, 
years, mean ± SD 
13.8 ± 6.9 12.0 ± 7.2 25 13.8 ± 6.9 13.8 ± 7.1 1 
Duration of diabetes, 
years, median (IQR) 
14 (9 to 19) 12 (6 to 17) 25 14 (9 to 19) 14 (8 to 20) 1 
  <1 year 699 (3.6) 1,357 (7.0) 15 699 (3.6) 696 (3.5) 1 
  1-4 years 1,707 (8.7) 2,435 (12.5) 12 1,707 (8.7) 1,767 (8.9) 1 
  5-9 years 3,611 (18.4) 4,303 (22.1) 9 3,611 (18.4) 3,733 (18.9) 1 
  10-19 years 9,319 (47.5) 8,114 (41.6) 12 9,319 (47.5) 8,984 (45.4) 4 
  20-29 years 4,275 (21.8) 3,274 (16.8) 13 4,275 (21.8) 4,595 (23.2) 3 
Diabetic retinopathy 168 (0.9) 140 (0.7) 2 168 (0.9) 172 (0.9) 0 
Diabetic neuropathy 231 (1.2) 257 (1.3) 1 231 (1.2) 223 (1.1) 1 
Hypoglycemia 115 (0.6) 185 (0.9) 3 115 (0.6) 127 (0.6) 0 
Hyperglycemic 
emergency  
47 (0.2) 82 (0.4) 4 47 (0.2) 75 (0.4) 4 
Prior acute kidney 
injury 
351 (1.8) 702 (3.6) 11 351 (1.8) 395 (2.0) 1 
Prior acute urinary 
retention 
252 (1.3) 452 (2.3) 8 252 (1.3) 237 (1.2) 1 
Chronic obstructive 
pulmonary disease 
396 (2.0) 490 (2.5) 3 396 (2.0) 453 (2.3) 2 
Chronic lung disease 3,885 (19.8) 3,976 (20.4) 1 3,885 (19.8) 4,049 (20.5) 2 
Cancer 5,586 (28.5) 5,987 (30.7) 5 5,586 (28.5) 5,579 (28.2) 1 
Stroke 270 (1.4) 556 (2.9) 10 270 (1.4) 256 (1.3) 1 
Atrial Fibrillation 717 (3.7) 930 (4.8) 5 717 (3.7) 702 (3.5) 1 
Ventricular arrhythmia 61 (0.3) 76 (0.4) 2 61 (0.3) 66 (0.3) 0 
Coronary artery bypass 
graft surgery 
513 (2.6) 372 (1.9) 5 513 (2.6) 514 (2.6) 0 
Percutaneous coronary 
intervention  
1,051 (5.4) 777 (4.0) 7 1,051 (5.4) 1,010 (5.1) 1 
Pacemaker 543 (2.8) 561 (2.9) 1 543 (2.8) 518 (2.6) 1 
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Congestive heart 
failure 
1,649 (8.4) 1,876 (9.6) 4 1,649 (8.4) 1,674 (8.5) 0 
Transplant - hepatic 8 (0.0) 7 (0.0) 4 8 (0.0) 9 (0.0) 0 
Chronic liver disease 947 (4.8) 978 (5.0) 1 947 (4.8) 916 (4.6) 1 
Coronary artery disease 6,665 (34.0) 5,985 (30.7) 7 6,665 (34.0) 6,669 (33.7) 1 
Peripheral vascular 
disease 
202 (1.0) 218 (1.1) 1 202 (1.0) 188 (1.0) 0 
Hypertension 15,302 (78.0) 13,528 (69.4) 20 15,302 (78.0) 15,477 (78.3) 1 
Hypotension 176 (0.9) 297 (1.5) 6 176 (0.9) 157 (0.8) 1 
Hyponatremia 202 (1.0) 393 (2.0) 8 202 (1.0) 203 (1.0) 0 
Influenza vaccination 14,066 (71.7) 13,393 (68.7) 7 14,066 (71.7) 13,912 (70.4) 3 
Prior respiratory 
infection 
12,540 (63.9) 12,169 (62.5) 3 12,540 (63.9) 12,559 (63.5) 1 
Prior skin & soft tissue 
infection 
19,428 (99.1) 19,112 (98.1) 9 19,428 (99.1) 19,602 (99.1) 0 
Prior other infections 6,343 (32.3) 6,299 (32.3) 0 6,343 (32.3) 6,391 (32.3) 0 
Hyperkalemia 85 (0.4) 131 (0.7) 4 85 (0.4) 86 (0.4) 0 
Urinary incontinence 195 (1.0) 209 (1.1) 1 195 (1.0) 177 (0.9) 1 
Urinary retention 252 (1.3) 452 (2.3) 8 252 (1.3) 237 (1.2) 1 
Prior urinary tract 
infections 
578 (2.9) 1,015 (5.2) 12 578 (2.9) 661 (3.3) 2 
Charlson comorbidity indexf 
Mean ± SD 0.3 ± 0.9 0.5 ± 1.2 14 0.3 ± 0.9 0.3 ± 1.0 1 
Median (IQR) 0 (0 to 0) 0 (0 to 0) 13 0 (0 to 0) 0 (0 to 0) 1 
  0 16,722 (85.3) 15,676 (80.5) 13 16,722 (85.3) 16,998 (86.0) 2 
  1 943 (4.8) 1,147 (5.9) 5 943 (4.8) 852 (4.3) 2 
  2 862 (4.4) 1,044 (5.4) 5 862 (4.4) 862 (4.4) 0 
  3  1,084 (5.5) 1,616 (8.3) 11 1,084 (5.5) 1,063 (5.4) 0 
Medicationsg 
ACE inhibitors  7,155 (36.5) 6,128 (31.5) 11 7,155 (36.5) 7,271 (36.8) 1 
ARB 4,754 (24.2) 4,095 (21.0) 8 4,754 (24.2) 4,856 (24.6) 1 
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ACE or ARB 11,796 (60.1) 10,124 (52.0) 16 11,796 (60.1) 12,008 (60.7) 1 
ACE and ARB 113 (0.6) 99 (0.5) 1 113 (0.6) 120 (0.6) 0 
Acetylsalicyclic acidh 436 (2.2) 395 (2.0) 1 436 (2.2) 497 (2.5) 2 
Beta blockers 6,427 (32.8) 5,679 (29.1) 8 6,427 (32.8) 6,442 (32.6) 0 
Calcium channel 
blockers 
6,167 (31.4) 5,540 (28.4) 7 6,167 (31.4) 6,205 (31.4) 0 
NSAIDsi 2,076 (10.6) 1,684 (8.6) 7 2,076 (10.6) 2,144 (10.8) 1 
Statins  14,887 (75.9) 12,257 (62.9) 28 14,887 (75.9) 15,031 (76.0) 0 
Proton pump inhibitors  4,264 (21.7) 4,137 (21.2) 1 4,264 (21.7) 4,352 (22.0) 1 
Picosalax 169 (0.9) 169 (0.9) 0 169 (0.9) 158 (0.8) 1 
Cephalosporins 823 (4.2) 849 (4.4) 1 823 (4.2) 870 (4.4) 1 
Lithium 23 (0.1) 28 (0.1) 0 23 (0.1) 30 (0.2) 3 
Amoxicillin 1,518 (7.7) 1,468 (7.5) 1 1,518 (7.7) 1,717 (8.7) 4 
Ciprofloxacin 434 (2.2) 561 (2.9) 4 434 (2.2) 494 (2.5) 2 
Norfloxacin 51 (0.3) 74 (0.4) 2 51 (0.3) 74 (0.4) 2 
Nitrofurantoin 377 (1.9) 566 (2.9) 7 377 (1.9) 501 (2.5) 4 
Sulfamethoxazole & 
trimethoprim 
159 (0.8) 220 (1.1) 3 159 (0.8) 203 (1.0) 2 
Overactive bladder 
medications 
329 (1.7) 352 (1.8) 1 329 (1.7) 345 (1.7) 0 
Loop diuretics  1,289 (6.6) 1,376 (7.1) 2 1,289 (6.6) 1,352 (6.8) 1 
Potassium sparing 
diuretics   
610 (3.1) 635 (3.3) 1 610 (3.1) 602 (3.0) 1 
Thiazide diuretics  2,700 (13.8) 2,608 (13.4) 1 2,700 (13.8) 2,874 (14.5) 2 
Any diuretic type 4,240 (21.6) 4,231 (21.7) 0 4,240 (21.6) 4,460 (22.6) 2 
Number of unique diuretic types   
  0 15,371 (78.4) 15,252 (78.3) 0 15,371 (78.4) 15,315 (77.4) 2 
  1 3,892 (19.8) 3,858 (19.8) 0 3,892 (19.8) 4,110 (20.8) 2 
  2 337 (1.7) 358 (1.8) 1 337 (1.7) 332 (1.7) 0 
  3 11 (0.1) 15 (0.1) 0 11 (0.1) 18 (0.1) 0 
Number of unique drug names   
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Mean ± SD 7.87 ± 4.07 6.91 ± 4.43 23 7.87 ± 4.07 8 ± 4.28 3 
Median (IQR) 7 (5 to 10) 7 (4 to 9) 24 7 (5 to 10) 8 (5 to 10) 3 
  0-4 drug names 3,654 (18.6) 5,916 (30.4) 28 3,654 (18.6) 3,837 (19.4) 2 
  5-9 drug names 10,179 (51.9) 8,698 (44.6) 15 10,179 (51.9) 9,633 (48.7) 6 
  10-15 drug names 4,924 (25.1) 4,113 (21.1) 10 4,924 (25.1) 5,286 (26.7) 4 
  15-19 drug names 625 (3.2) 554 (2.8) 2 625 (3.2) 747 (3.8) 3 
  20+ drug names  229 (1.2) 202 (1.0) 2 229 (1.2) 273 (1.4) 2 
Hypoglycemic medications dispensed in prior 120 days 
Insulin 5,229 (26.7) 2,508 (12.9) 35 5,229 (26.7) 5,582 (28.2) 3 
Acarbose 366 (1.9) 141 (0.7) 11 366 (1.9) 447 (2.3) 3 
Gliclazide 6,606 (33.7) 4,385 (22.5) 25 6,606 (33.7) 6,870 (34.7) 2 
Glyburide 719 (3.7) 1,004 (5.2) 7 719 (3.7) 740 (3.7) 0 
Metformin 15,765 (80.4) 12,738 (65.4) 34 15,765 (80.4) 15,837 (80.1) 1 
Repaglinide 6 (0.0) 10 (0.1) 4 6 (0.0) 23 (0.1) 4 
Rosiglitazone maleate 13 (0.1) 16 (0.1) 0 13 (0.1) 12 (0.1) 0 
Pioglitazine 100 (0.5) 104 (0.5) 0 100 (0.5) 108 (0.5) 0 
Hypoglycemic medications dispensed on the cohort entry date 
Insulin 1,153 (5.9) 803 (4.1) 8 1,153 (5.9) 1,110 (5.6) 1 
Acarbose 122 (0.6) 105 (0.5) 1 122 (0.6) 126 (0.6) 0 
Gliclazide 2,077 (10.6) 2,176 (11.2) 2 2,077 (10.6) 1,946 (9.8) 3 
Glyburide 172 (0.9) 292 (1.5) 6 172 (0.9) 159 (0.8) 1 
Metformin 5,589 (28.5) 5,422 (27.8) 2 5,589 (28.5) 5,439 (27.5) 2 
Pioglitazine 26 (0.1) 9 (0.0) 4 26 (0.1) 7 (0.0) 4 
Hypoglycemic medications dispensed in the 1 year to 120 days before the cohort entry date 
Insulin 5,664 (28.9) 2,877 (14.8) 35 5,664 (28.9) 5,997 (30.3) 3 
Acarbose 445 (2.3) 217 (1.1) 9 445 (2.3) 522 (2.6) 2 
Gliclazide 7,457 (38.0) 5,459 (28.0) 21 7,457 (38.0) 7,672 (38.8) 2 
Glyburide 1,003 (5.1) 1,419 (7.3) 9 1,003 (5.1) 1,025 (5.2) 0 
Metformin 16,698 (85.1) 14,552 (74.7) 26 16,698 (85.1) 16,695 (84.4) 2 
Repaglinide 7 (0.0) 20 (0.1) 4 7 (0.0) 28 (0.1) 4 
Rosiglitazone maleate 19 (0.1) 22 (0.1) 0 19 (0.1) 15 (0.1) 0 
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Pioglitazine 125 (0.6) 141 (0.7) 1 125 (0.6) 148 (0.7) 1 
Healthcare use in the past 1 year 
Number of any hospitalizations   
Mean ± SD 0.12 ± 0.45 0.22 ± 0.65 18 0.12 ± 0.45 0.12 ± 0.44 0 
Median (IQR) 0 (0 to 0) 0 (0 to 0) 18 0 (0 to 0) 0 (0 to 0) 1 
  0 visits 17,821 (90.9) 16,618 (85.3) 17 17,821 (90.9) 18,001 (91.0) 0 
  1 visit 1,364 (7.0) 1,977 (10.1) 11 1,364 (7.0) 1,378 (7.0) 0 
  2 visits 314 (1.6) 562 (2.9) 9 314 (1.6) 289 (1.5) 1 
  3+ visits 112 (0.6) 326 (1.7) 10 112 (0.6) 107 (0.5) 1 
Number of any ED visits 
Mean ± SD 0.5 ± 1.24 0.69 ± 1.57 13 0.5 ± 1.24 0.52 ± 1.12 2 
Median (IQR) 0 (0 to 1) 0 (0 to 1) 16 0 (0 to 1) 0 (0 to 1) 2 
  0 visits 14,234 (72.6) 12,840 (65.9) 15 14,234 (72.6) 14,009 (70.8) 4 
  1 visit 3,292 (16.8) 3,596 (18.5) 4 3,292 (16.8) 3,487 (17.6) 2 
  2 visits 1,136 (5.8) 1,527 (7.8) 8 1,136 (5.8) 1,256 (6.4) 3 
  3+ visits 949 (4.8) 1,520 (7.8) 12 949 (4.8) 1,023 (5.2) 2 
GP/FP visits  
Mean ± SD 8.22 ± 6.72 9.37 ± 9.93 14 8.22 ± 6.72 8.12 ± 6.79 1 
Median (IQR) 7 (4 to 10) 7 (4 to 11) 5 7 (4 to 10) 7 (4 to 10) 1 
  0 visits 460 (2.3) 493 (2.5) 1 460 (2.3) 597 (3.0) 4 
  1-2 visits 1,702 (8.7) 1,788 (9.2) 2 1,702 (8.7) 1,707 (8.6) 0 
  3-4 visits 3,462 (17.7) 3,256 (16.7) 3 3,462 (17.7) 3,457 (17.5) 1 
  5-6 visits 3,824 (19.5) 3,629 (18.6) 2 3,824 (19.5) 4,090 (20.7) 3 
  7-8 visits 3,101 (15.8) 2,853 (14.6) 3 3,101 (15.8) 3,076 (15.6) 1 
  9-10 visits 2,222 (11.3) 1,988 (10.2) 4 2,222 (11.3) 2,033 (10.3) 3 
  11+ visits 4,840 (24.7) 5,476 (28.1) 8 4,840 (24.7) 4,814 (24.3) 1 
Cardiologist visits  
Mean ± SD 1.12 ± 2.36 1.25 ± 2.72 5 1.12 ± 2.36 1.12 ± 2.26 0 
Median (IQR) 0 (0 to 1) 0 (0 to 1) 2 0 (0 to 1) 0 (0 to 1) 0 
  0 visits 11,273 (57.5) 11,042 (56.7) 2 11,273 (57.5) 11,397 (57.6) 0 
  1 visit 3,882 (19.8) 3,875 (19.9) 0 3,882 (19.8) 3,859 (19.5) 1 
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  2 visits 1,782 (9.1) 1,701 (8.7) 1 1,782 (9.1) 1,723 (8.7) 1 
  3+ visits 2,674 (13.6) 2,865 (14.7) 3 2,674 (13.6) 2,795 (14.1) 1 
Opthamologist visits 
Mean ± SD 1.02 ± 2.24 0.95 ± 2.14 3 1.02 ± 2.24 1.03 ± 2.27 0 
Median (IQR) 0 (0 to 1) 0 (0 to 1) 4 0 (0 to 1) 0 (0 to 1) 1 
  0 visits 12,927 (65.9) 13,196 (67.7) 4 12,927 (65.9) 13,015 (65.8) 0 
  1 visit 2,828 (14.4) 2,627 (13.5) 3 2,828 (14.4) 2,814 (14.2) 1 
  2 visits 1,386 (7.1) 1,354 (6.9) 1 1,386 (7.1) 1,399 (7.1) 0 
  3+ visits 2,470 (12.6) 2,306 (11.8) 2 2,470 (12.6) 2,547 (12.9) 1 
Endocrinologist visits 
Mean ± SD 0.6 ± 1.31 0.34 ± 1.21 21 0.6 ± 1.31 0.59 ± 1.37 1 
Median (IQR) 0 (0 to 0) 0 (0 to 0) 29 0 (0 to 0) 0 (0 to 0) 1 
  0 visits 14,809 (75.5) 16,879 (86.6) 29 14,809 (75.5) 15,214 (76.9) 3 
  1 visit 1,422 (7.3) 957 (4.9) 10 1,422 (7.3) 1,402 (7.1) 1 
  2 visits 1,485 (7.6) 764 (3.9) 16 1,485 (7.6) 1,301 (6.6) 4 
  3+ visits 1,895 (9.7) 883 (4.5) 20 1,895 (9.7) 1,858 (9.4) 1 
Nephrologist visits 
Mean ± SD 0.11 ± 0.67 0.14 ± 1.12 3 0.11 ± 0.67 0.11 ± 0.57 0 
Median (IQR) 0 (0 to 0) 0 (0 to 0) 5 0 (0 to 0) 0 (0 to 0) 0 
  0 visits 18,607 (94.9) 18,249 (93.7) 5 18,607 (94.9) 18,676 (94.4) 2 
  1 visit 501 (2.6) 624 (3.2) 4 501 (2.6) 498 (2.5) 1 
  2 visits 286 (1.5) 333 (1.7) 2 286 (1.5) 350 (1.8) 2 
  3+ visits 217 (1.1) 277 (1.4) 3 217 (1.1) 250 (1.3) 2 
Diabetes management 11,451 (58.4) 10,080 (51.7) 13 11,451 (58.4) 11,805 (59.7) 3 
Diabetes incentive 6,855 (35.0) 5,782 (29.7) 11 6,855 (35.0) 7,072 (35.8) 2 
Diabetes management 
by a specialist 
964 (4.9) 289 (1.5) 19 964 (4.9) 925 (4.7) 1 
Diabetes management 
by a specialist team 
487 (2.5) 112 (0.6) 15 487 (2.5) 447 (2.3) 1 
Cholesterol tests 17,740 (90.5) 16,929 (86.9) 11 17,740 (90.5) 17,897 (90.5) 0 
Proteinuria 10,453 (53.3) 10,905 (56.0) 5 10,453 (53.3) 10,624 (53.7) 1 
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SCr tests 19,026 (97.0) 18,519 (95.1) 10 19,026 (97.0) 19,180 (97.0) 0 
Glucose tests 17,881 (91.2) 17,288 (88.7) 8 17,881 (91.2) 17,948 (90.8) 1 
HbA1c tests 18,996 (96.9) 18,401 (94.4) 12 18,996 (96.9) 19,152 (96.8) 0 
DVT/PE 21 (0.1) 48 (0.2) 3 21 (0.1) 22 (0.1) 0 
Bone mineral density 
test 
1,201 (6.1) 1,357 (7.0) 4 1,201 (6.1) 1,211 (6.1) 0 
Hearing test 866 (4.4) 792 (4.1) 1 866 (4.4) 814 (4.1) 1 
Sputum 35 (0.2) 52 (0.3) 2 35 (0.2) 54 (0.3) 2 
Wound swab 14 (0.1) 18 (0.1) 0 14 (0.1) 17 (0.1) 0 
Holter monitoring 1,546 (7.9) 1,605 (8.2) 1 1,546 (7.9) 1,576 (8.0) 0 
Cardiac stress test 3,124 (15.9) 2,519 (12.9) 9 3,124 (15.9) 3,064 (15.5) 1 
Coronary 
revascularization 
382 (1.9) 292 (1.5) 3 382 (1.9) 338 (1.7) 2 
Electrocardiography 9,239 (47.1) 9,809 (50.3) 6 9,239 (47.1) 9,251 (46.8) 1 
Pulmonary function 
test 
2,244 (11.4) 2,051 (10.5) 3 2,244 (11.4) 2,156 (10.9) 2 
At-home physician 
service 
252 (1.3) 481 (2.5) 9 252 (1.3) 237 (1.2) 1 
Urinalysis 10,684 (54.5) 11,202 (57.5) 6 10,684 (54.5) 10,864 (54.9) 1 
Cystoscopy 612 (3.1) 778 (4.0) 5 612 (3.1) 600 (3.0) 1 
Transurethral resection 
of the prostate 
71 (0.4) 81 (0.4) 0 71 (0.4) 53 (0.3) 2 
Carotid ultrasound 901 (4.6) 994 (5.1) 2 901 (4.6) 942 (4.8) 1 
Cardiac catheterization  661 (3.4) 503 (2.6) 5 661 (3.4) 587 (3.0) 2 
Coronary angiogram 648 (3.3) 494 (2.5) 5 648 (3.3) 575 (2.9) 2 
Electroencephalograph
y 
51 (0.3) 138 (0.7) 6 51 (0.3) 50 (0.3) 0 
Chest x-ray 4,899 (25.0) 5,929 (30.4) 12 4,899 (25.0) 4,964 (25.1) 0 
Echocardiography 4,377 (22.3) 4,262 (21.9) 1 4,377 (22.3) 4,387 (22.2) 0 
Prostate-specific 
antigen test 
1,124 (5.7) 845 (4.3) 6 1,124 (5.7) 1,109 (5.6) 0 
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Cervical cancer 
screening 
641 (3.3) 531 (2.7) 4 641 (3.3) 614 (3.1) 1 
Laboratory testsj 
Baseline eGFRk, ml/min/1.73m2 
Mean ± SD 76.7 ± 13.9 72.9 ± 15.6 26 76.7 ± 13.9 76.7 ± 15.6 0 
Median (IQR) 78 (66 to 88) 74 (59 to 87) 24 78 (66 to 88) 80 (64 to 90) 0 
  >60 ml/min/1.73m2 16,786 (85.6) 14,405 (73.9) 29 16,786 (85.6) 16,009 (81.0) 12l 
  45-60 ml/min/1.73m2 2,825 (14.4) 5,078 (26.1) 29 2,825 (14.4) 3,766 (19.0) 12l 
Time from most recent SCr test to cohort entry date  
Mean ± SD 61.9 ± 75.6 63.8 ± 83.6 2 61.9 ± 75.6 59.7 ± 78.5 3 
Median (IQR) 28 (9 to 89) 24 (8 to 88) 6 28 (9 to 89) 23 (8 to 81) 3 
Baseline SCr, µmol/L 
Mean ± SD 79.7 ± 18.1 81.2 ± 20.2 8 79.7 ± 18.1 79.7 ± 20.3 0 
Median (IQR) 78 (66 to 91) 79 (66 to 94) 6 78 (66 to 91) 77 (65 to 92) 1 
Baseline potassium, mEq/L 
Potassium data 
available 
5,556 (28.3) 7,072 (36.3) 17 5,556 (28.3) 6,110 (30.9) 6 
Mean ± SD 4.5 ± 0.5 4.4 ± 0.5 13 4.5 ± 0.5 4.5 ± 0.4 7 
Median (IQR) 5 (4 to 5) 4 (4 to 5) 11 5 (4 to 5) 5 (4 to 5) 5 
Time from most recent ACR test to cohort entry date   
Mean ± SD 67.8 ± 90.5 61.4 ± 93.9 7 67.8 ± 90.5 65.2 ± 93.1 3 
Median (IQR) 20 (0 to 106) 10 (0 to 91) 19 20 (0 to 106) 16 (0 to 101) 3 
Baseline ACR categories, mg/mmol 
ACR data available  14,637 (74.6) 12,381 (63.5) 24 14,637 (74.6) 14,240 (72.0) 6 
Undetected 9,424 (48.1) 7,903 (40.6) 15 9,424 (48.1) 9,129 (46.2) 4 
3-30 4,263 (21.7) 3,729 (19.1) 6 4,263 (21.7) 4,288 (21.7) 0 
>30 950 (4.8) 749 (3.8) 5 950 (4.8) 823 (4.2) 3 
Most recent glycated hemoglobin level, % 
Glycated hemoglobin 
value available 
6,516 (33.2) 8,071 (41.4) 17 6,516 (33.2) 7,288 (36.9) 8 
Mean ± SD 7.8 ± 1.2 7.7 ± 1.3 12 7.8 ± 1.2 7.8 ± 1.2 2 
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Median (IQR) 8 (7 to 8) 7 (7 to 8) 16 8 (7 to 8) 8 (7 to 8) 3 
  <6 89 (1.4) 224 (2.8) 7 89 (1.4) 129 (1.8) 3 
  6-<6.5 392 (6.0) 686 (8.5) 9 392 (6.0) 468 (6.4) 3 
  6.5-<7.0 1,018 (15.6) 1,500 (18.6) 10 1,018 (15.6) 1,175 (16.1) 3 
  7.0-<7.5 1,334 (20.5) 1,688 (20.9) 7 1,334 (20.5) 1,483 (20.3) 3 
  ≥7.5 3,683 (56.5) 3,973 (49.2) 4 3,683 (56.5) 4,032 (55.3) 4 
KFREm data, % 
2-year KFRE data 
available 
14,637 (74.6) 12,381 (63.5) 24 14,637 (74.6) 14,240 (72.0) 6 
  <5% 14,637 (100) 12,381 (100) 1 14,638 (100) 14,240 (100) 6 
5-year KFRE data 
available 
14,637 (74.6) 12,381 (63.5) 24 14,637 (74.6) 14,240 (72.0) 6 
  <5% 14,616 (99.9) 12,345 (99.7) 1 14,616 (99.9) 14,200 (99.7) 6 
  5%+ 21 (0.1) 36 (0.3) 1 21 (0.1) 40 (0.3) 3 
Abbreviations: ACE= angiotensin-converting–enzyme, ACR= albumin-to-creatinine ratio, ARB= angiotensin-receptor blocker, 
DPP4= dipeptidyl peptidase-4, DVT/PE= deep vein thrombosis and pulmonary embolism, ED= emergency department, eGFR = 
estimated glomerular filtration, GP/FP= general practice/family practice, HbA1c= glycated hemoglobin, IQR= interquartile range, 
KFRE= kidney failure risk equation, NSAID= nonsteroidal anti-inflammatory drug, SCr= serum creatinine, SD= standard deviation, 
SGLT2= sodium-glucose cotransporter-2 
aUnless otherwise specified, baseline characteristics were assessed on the date the patient filled their prescription: the cohort entry 
date. 
bWeighted using inverse probability of treatment weighting based on propensity scores, using weights to estimate the average 
treatment effect in the treated. Patients in the reference group were weighted as [propensity score/(1 - propensity score)]. This method 
produces a weighted pseudo-sample of patients in the reference group with the same distribution of measured covariates as the 
exposure group (71,73,74). 
cThe difference between the groups divided by the pooled SD; a value greater than 10% is interpreted as a meaningful difference (83). 
dRural residence was defined as a population < 10,000 people. Residential information was not available for 33 (0.2%) SGLT2 
inhibitor users and 18 (0.1%) DPP4 inhibitor users in the unweighted cohort. Missing values in the unweighted cohort were re-
classified into the “Not rural” category during weighting. 
eIncome was categorized into fifths of average neighborhood income on the cohort entry date. Socioeconomic status was missing for 
33 (0.2%) of SGLT2 inhibitor users and 18 (0.1%) of DPP4 inhibitor users. 
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fCharlson comorbidity index (106,107) was calculated using five years of hospitalization data. “No hospitalizations” received a score 
of 0. A higher score indicates a higher risk of one-year mortality associated with comorbidities.  
gMedication use was examined in the 120-day period before the cohort entry date (the Ontario Drug Benefit program dispenses a 
maximum 100-day supply. 
hOnly included dispensed acetylsalicyclic acid use and does not account for over-the-counter acetylsalicyclic acid use.  
iExcludes acetylsalicylic acid and does not account for over-the-counter NSAID use. 
jMost recent laboratory test values in the 1-to-365–day period before the cohort entry date. 
keGFR was calculated using the Chronic Kidney Disease (CKD)–Epidemiology (EPI) equation: 141 × min([serum creatinine 
concentration in μmol/L/88.4]/ĸ, 1)α × max([serum creatinine concentration in μmol/L/88.4]/ĸ, 1)-1.209 × 0.993Age × 1.018 [if 
female] × 1.159 [if African-American]; ĸ=0.7 if female and 0.9 if male; α=-0.329 if female and -0.411 if male; min=the minimum of 
serum creatinine concentration/ĸ or 1; max=the maximum of serum creatinine concentration/ĸ or 1. Information on race was not 
available in our data sources and all patients were assumed not to be of African-Canadian race; African-Canadians represented less 
than 5% of the population of Ontario in 2006. 
lAlthough the groups were still imbalanced on eGFR categories after weighting, there was no statistical or clinically meaningful 
difference when baseline eGFR was assessed as a continuous variable. 
mKFRE is based on a prediction model for progression to kidney failure (108). The equation includes age, sex, eGFR and albuminuria. 
A higher percentage indicates a greater 2- and 5-year chance of developing treated end-stage kidney disease. 
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Table 3. 90-day primary and secondary outcomes of prescription SGLT2 inhibitor new users compared with DPP4 inhibitor new users 
 
 
Observed Weightedb 
No. events (%) No. events (%) 
Risk difference, % 
(95% CI) 
Risk ratio 
(95% CI) 
P-
value 
SGLT2 
inhibitors 
(n=19,611) 
DPP4 
inhibitors 
(n=19,483) 
SGLT2 
inhibitors 
(n=19,611) 
DPP4 
inhibitors 
(n=19,775) 
Primary outcome 
Hospital encounter 
with acute kidney 
injuryc 
216 (1.10%) 388 (1.99%) 216 (1.10%) 
275 
(1.39%) 
-0.29% 
(-0.57% to -0.01%) 
0.79 
(0.64 to 0.98) 
0.04 
Secondary outcomes        
Hospitalization with 
acute kidney injury 
149 (0.76%) 291 (1.49%) 149 (0.76%) 
206 
(1.04%) 
-0.28% 
(-0.53% to -0.03%) 
0.73 
(0.56 to 0.95) 
0.02 
Hospital encounter 
with moderate to 
severe acute kidney 
injuryd 
44 (0.22%) 74 (0.38%) 44 (0.22%) 55 (0.28%) 
-0.05% 
(-0.18% to 0.08%) 
0.81 
(0.49 to 1.33) 
0.40 
Acute kidney injury 
restricted to outpatient 
setting  
573 (2.92%) 609 (3.13%) 573 (2.92%) 
513 
(2.60%) 
0.33% 
(-0.12% to 0.77%) 
1.13 
(0.95 to 1.33) 0.16 
Acute kidney injury 
in all settings 
716 (3.65%) 837 (4.30%) 716 (3.65%) 
681 
(3.44%) 
0.21% 
(-0.28% to 0.70%) 
1.06 
(0.92 to 1.22) 
0.42 
Abbreviations: CI= confidence interval, DPP4= dipeptidyl peptidase-4, SGLT2= sodium-glucose cotransporter-2 
aReference group: DPP4 inhibitor users.  
bWeighted using inverse probability of treatment weighting based on propensity scores, using weights to estimate the average t reatment effect in the 
treated.  
cBased on hospital presentation (emergency department or hospitalization) assessed using the Ontario Laboratories Information System serum 
creatinine values. This was defined by the 2012 KDIGO thresholds: compared with baseline, a serum creatinine increase ≥ 50% or an absolute 
increase of at least 27 µmol/L (0.3 mg/dL) (27).  
dDefined according to KDIGO staging thresholds of stages 2 and 3 combined (27). 
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Figure 2. Association between SGLT2 inhibitor new use (canagliflozin, dapagliflozin or 
empagliflozin) and the 90-day risk of hospital encounter with AKI examined in 
subgroups defined by baseline eGFR, ACEi or ARB use, diuretic use and age 
 
Abbreviations: ACEi= angiotensin-converting-enzyme inhibitor, ARB= angiotensin 
receptor blocker, CI= confidence interval, DPP4i= dipeptidyl peptidase-4 inhibitor, 
eGFR= estimated glomerular filtration rate, N/A= not applicable, SGLT2i= sodium-
glucose cotransporter-2 inhibitor 
aDiuretic types included loop diuretics, potassium sparring diuretics and thiazide diuretics 
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Chapter 6  
6 Discussion 
6.1 Summary and interpretation of study results 
In this large population-based cohort study of older adults, we did not observe a higher 
risk of AKI in new users of SGLT2 inhibitors compared with DPP4 inhibitors in any 
analysis. Rather, we observed that new use of an SGLT2 inhibitor was associated with a 
lower 90-day risk of a hospital encounter with AKI. Results remained robust when the 
follow-up was extended to one year. When four subgroups of higher risk patients were 
examined, none showed evidence of a higher 90-day risk of AKI following new SGLT2 
inhibitor use compared to DPP4 inhibitor use.  
These findings are reassuring for the safety of SGLT2 inhibitors as currently prescribed 
in routine care. A likely explanation to this observed protective effect is the, now better 
understood, mechanism by which SGLT2 inhibitors have demonstrated several 
nephroprotective features akin to ACE inhibitors and ARB initiation (45,46,109), 
including a reduction in albuminuria and risk of progressive chronic kidney disease 
(110,111). The cardiovascular benefits of SGLT2 inhibitors may also result in renal 
benefits, given how dependent the kidney is on cardiac function.  
Our demonstration of a 21% lower relative risk of AKI is consistent with three published 
observational cohort studies (15–17). Two of these studies also used laboratory data to 
define AKI (albeit in relatively smaller sample sizes) and both found a >50% lower AKI 
risk following SGLT2 inhibitor use (15,16). The most recent observational study with the 
most comparable sample size to this current study found SGLT2 inhibitor use versus 
GLP1 receptor agonist use resulted in a 31% reduction in AKI risk, but was not 
statistically significant (17).  
Some might suggest cohort studies suffer from residual confounding leading to spurious 
associations. For example, before weighting patients in this study, newly dispensed 
SGLT2 inhibitor users demonstrated less comorbidity and better maintained kidney 
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function than DPP4 inhibitor users, which might explain the observed lower risk of AKI 
with SGLT2 inhibitors even after weighting. However, our results were very similar to 
the findings of large recent RCTs and meta-analyses of RCTs. In the CREDENCE study, 
patients with type 2 diabetes and chronic kidney disease, who were randomized to receive 
canagliflozin, had a lower non-significant risk of AKI compared with placebo (7). A 
recent systematic review and meta-analysis by Neuen et al. of over 38,723 participants 
from RCTs demonstrated a similar significant 25% reduction in AKI risk with SGLT2 
inhibitor use versus placebo (111). A systematic review and meta-analysis by Toyama et 
al, of over 7,000 patients from RCTs demonstrated a 31% reduction in AKI risk with 
SGLT2 inhibitor use versus placebo, but was not statistically significant (112). Another 
meta-analysis of the three major RCTs demonstrated a 34% statistically significant 
relative risk reduction in the likelihood of AKI amongst those randomized to receive 
SGLT2 inhibitors versus placebo (113).  
The totality of randomized and routine care evidence suggests regulatory warnings and 
prescribing references about a higher AKI risk with SGLT2 inhibitors may be 
unwarranted and might be reconsidered (1,114).  
 
6.2 Strengths and limitations  
Our study has several strengths. It is the largest population-based study to date to assess 
the risk of a clinically important complication of SGLT2 inhibitor use among older 
adults. It is the first Canadian study to evaluate AKI risk in association with an important 
medication that is likely to be used more often in response to recent trials demonstrating 
its benefits (4,6,7). We used laboratory values, as opposed to diagnostic codes, to more 
specifically capture AKI events associated with SGLT2 inhibitor initiation (115,116). We 
selected patients who filled a prescription for a different class of oral hypoglycemic 
medications as our comparator group to avoid confounding by indication bias that would 
arise if we simply examined SGLT2 inhibitor non-users. 
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There are several limitations to our study. Given the observational study design, causality 
cannot be inferred. Although we chose an active comparator drug that is also 2nd or 3rd 
line medication for diabetes and we balanced on 97 measured baseline characteristics, 
confounding by indication cannot be ruled out. When estimating eGFRs using the CKD-
EPI equation, we had no information about race and assumed all patients to be non-black 
for the CKD-EPI equation (<5% of the Ontario population is of black race) (70). Thus, 
eGFR values for black patients may not be estimated accurately. In addition, we cannot 
account for whether strategies such as sick day management of diabetes medications (i.e. 
stopping SGLT2 inhibitors during acute illness) altered the risk of AKI. Although 
residual confounding cannot be eliminated, we attempted to reduce it using IPTW and 
balanced patients on over 95 characteristics. We also conducted several additional 
sensitivity analyses which supported the main findings. In particular, the magnitude of 
the E-value, along with the entire context of this study, suggest the observed association 
is unlikely to be explained by unmeasured confounding. Some confounders that could not 
be captured in our datasets may be smoking status, body mass index, and oral water 
intake which when poor may predispose to volume depletion (30,117–120). However, we 
have no reason to believe that these factors would be differentially more prevalent 
amongst SGLT2i users compared to DPP4i users. 
Additional limitations were that we could only identify prescriptions dispensed by a 
pharmacy but had no information about medication use or adherence. We only included 
patients aged over 66 years, but our study findings are consistent with studies that 
included adults of all ages (16,17). The 2012 KDIGO definition of AKI includes timing 
elements for when SCr measurements needed to be taken within (increase in SCr within 
48 hours and a baseline measurement presumed to have occurred within the prior 7 days), 
which were not considered in the current study outcome definitions (27). The SCr 
measurements were done as per routine care and about half of the patients did not have a 
SCr measurement during the 90-day follow-up period. While we observed a significant 
between-group difference in the likelihood of SCr measurement in follow-up, the 
absolute difference was not large and we believe it unlikely to affect the overall results. 
Following SGLT2 inhibitor initiation clinicians may be more likely to check SCr, 
especially in higher risk patients, compared to our comparator group, which could lead to 
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a greater (not lower) risk of SGLT2 inhibitor-associated AKI. Lastly, it is important to 
note that the population studied was of lower risk of AKI, largely based on well-
preserved kidney function and minimal or no albuminuria. Extrapolation of the findings 
to higher risk patients should be done with caution.  
 
6.3 Implications 
In older adults in routine clinical practice, new initiation of an SGLT2 inhibitor compared 
with DPP4 inhibitors was associated with a lower 90-day AKI risk. This is reassuring for 
prescribers, as SCr expectedly increased following SGLT2 inhibitor initiation, but did not 
appear to lead to AKI. Taken together with consistent information from other studies, 
regulatory warnings about a higher risk of AKI with SGLT2 inhibitors may be 
unwarranted and should be revisited. 
Consideration can be given to future trials of SGLT2 inhibitor use in patient settings 
where the timing and risk of AKI is both predictable and high, such as in the 
perioperative setting. As the uptake of SGLT2 inhibitors expands, we will likely see the 
drug used by more patients with advanced chronic kidney disease, where the risk-benefit 
balance requires attention. Also, better information on the effects of withholding these 
drugs in the context of acute illness or infection warrants attention.  
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Appendices 
Appendix A. Regulatory warnings on the risk of acute kidney injury with SGLT2 
inhibitor use (8,9) 
 
Study Drug Summary of Warning 
Canagliflozin - In October 2015, Health Canada released a summary of the safety 
review which reported a risk of acute kidney injury following 
canagliflozin use. This review was based on reports of acute kidney injury 
both to Health Canada and international reports. In addition, scientific 
literature was reviewed at the time and it was noted that the drug’s renal 
effects might be a potential problem (8). 
- In June 2016, the United States Food and Drug Administration (FDA) 
strengthened kidney warnings for canagliflozin based on a search of the 
FDA adverse event reporting system identifying 101 patients with 
sufficient detail to confirm the diagnosis and show a temporal relationship 
with canagliflozin (9). 
Empagliflozin - No warning about the risk of acute kidney injury following the use of 
empagliflozin. 
- However, in an FDA briefing document discussing the supplemental 
new drug application for empagliflozin using data from the EMPA-REG 
OUTCOME trial (released shortly after the warnings were issued for 
canagliflozin and dapagliflozin), there was a section stating that the risk 
of acute kidney injury with empagliflozin is slightly increased compared 
to placebo due to the diuretic activity of the drug leading to an early 
hemodynamic effect on renal function. In both the first 30 days and first 
90 days following empagliflozin use, the incidence of early renal adverse 
events was greater in empagliflozin users (121). 
Dapagliflozin - In October 2015, Health Canada released a summary of the safety 
review which reported a risk of acute kidney injury following 
dapagliflozin use. This review was based on reports of acute kidney 
injury both to Health Canada and international reports. In addition, 
scientific literature was reviewed at the time it was noted that the drug’s 
renal effects might be a potential problem (8). 
- In June 2016, the United States Food and Drug Administration (FDA) 
strengthened kidney warnings for dapagliflozin based on a search of the 
FDA adverse event reporting system identifying 101 patients with 
sufficient detail to confirm the diagnosis and show a temporal relationship 
with dapagliflozin (9). 
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Appendix B. Standard daily doses of SGLT2 inhibitors and DPP4 inhibitors  
 
Drug Standard daily drug doses (mg) 
SGLT2 inhibitors 
Canagliflozin 100 or 300 
Empagliflozin 10 or 25  
Dapagliflozin 5 or 10  
 
DPP4 inhibitors 
Saxagliptin 2.5 or 5  
Sitagliptin 25, 50 or 100 
Linagliptin 5 
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Appendix C. Search strategies for literature review 
 
Database  Search Terms 
OVID 
Medline 
1 Acute Kidney Injury/ 
2 ((kidney or renal) adj3 (insufficien* or injur* or fail*)).mp. 
3 1 or 2 
4 Sodium-Glucose Transporter 2/ 
5 
(empagliflozin or dapagliflozin or canagliflozin or invokana 
or forxiga or jardiance).mp. 
6 4 or 5 
7 3 and 6 
RESULTS 261 
 Ovid MEDLINE(R) ALL <1946 to July 10, 2019> 
 
OVID 
Embase 
1 acute kidney failure/ 
2 ((kidney or renal) adj3 (insufficien* or injur* or fail*)).mp. 
3 
sodium glucose cotransporter 2/ or sodium glucose 
cotransporter 2 inhibitor/ 
4 
(empagliflozin or dapagliflozin or canagliflozin or invokana 
or forxiga or jardiance).mp. 
5 1 or 2 
6 3 or 4 
7 5 and 6 
RESULTS 983 
 Embase Classic+Embase <1947 to 2019 July 10>  
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Appendix D. REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement for 
Pharmacoepidemiology (RECORD-PE) (58) 
 
Item 
No 
STROBE items RECORD items RECORD-PE items Section 
Title and abstract 
1 (a) Indicate the study’s design with 
a commonly used term in the title or 
the abstract. 
(b) Provide in the abstract an 
informative and balanced summary 
of what was done 
and what was found. 
1.1: The type of data used 
should be specified in the title 
or abstract. 
When possible, the name of 
the databases used should be 
included. 
1.2: If applicable, the 
geographical region and 
timeframe within which the 
study took place should be 
reported in the title or abstract. 
1.3: If linkage between 
databases was conducted for 
the study, this should be 
clearly stated in the title or 
abstract. 
— 
Title & 
Abstract 
 
Introduction 
Background rationale 
2 Explain the scientific background 
and rationale for the investigation 
being reported. 
— — 
Chapter 1 & 2 
Objectives 
3 State specific objectives, including — — Chapter 3 
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any 
prespecified hypotheses. 
Methods     
Study design 
4 Present key elements of study 
design early in the paper. 
— 4.a: Include details of the specific 
study 
design (and its features) and report 
the 
use of multiple designs if used. 
4.b: The use of a diagram(s) is 
recommended to illustrate key 
aspects of 
the study design(s), including 
exposure, washout, lag and 
observation periods, and covariate 
definitions as relevant. 
Chapter 4 
Setting 
5 Describe the setting, locations, and 
relevant dates, including periods of 
recruitment, exposure, follow-up, 
and data collection. 
— — 
Chapter 4 
Participants 
6 (a) Cohort study—give the 
eligibility criteria, and the sources 
and methods of selection of 
participants. Describe methods of 
follow-up. Case-control study—give 
the eligibility criteria, and the 
sources and methods of case 
ascertainment and control selection. 
6.1: The methods of study 
population selection (such as 
codes or algorithms used to 
identify participants) should be 
listed in detail. If this is not 
possible, an explanation 
should be provided. 
6.2: Any validation studies of 
6.1.a: Describe the study entry 
criteria and the order in which these 
criteria were applied to identify the 
study population. 
Specify whether only users with a 
specific indication were included and 
whether patients were allowed to 
enter the study population once or if 
Chapter 4 
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Give the rationale for the choice of 
cases and controls. Cross sectional 
study—give the eligibility criteria, 
and the sources and methods of 
selection of participants. 
(b) Cohort study—for matched 
studies, give matching criteria and 
number of exposed and unexposed. 
Case-control 
study—for matched studies, give 
matching criteria and the number of 
controls per case. 
the codes or algorithms used to 
select the population should be 
referenced. If validation was 
conducted for this study and 
not published elsewhere, 
detailed methods and results 
should be provided. 
6.3: If the study involved 
linkage of databases, consider 
use of a flow diagram or other 
graphical display to 
demonstrate the data linkage 
process, including the number 
of individuals with linked data 
at each stage. 
 
 
multiple entries were permitted. See 
explanatory document for guidance 
related to matched designs. 
Variables 
7 Clearly define all outcomes, 
exposures, 
predictors, potential confounders, 
and effect modifiers. Give 
diagnostic criteria, if applicable. 
7.1: A complete list of codes 
and 
algorithms used to classify 
exposures, outcomes, 
confounders, 
and effect modifiers should be 
provided. If these cannot be 
reported, an explanation 
should be provided. 
 
7.1.a: Describe how the drug 
exposure definition was developed. 
7.1.b: Specify the data sources from 
which drug exposure information for 
individuals was obtained. 
7.1.c: Describe the time window(s) 
during which an individual is 
considered exposed to the drug(s). 
The rationale for\ selecting a 
particular time window should be 
provided. The extent of potential left 
truncation or left censoring should be 
specified. 
Chapter 4 
•Codes for 
baseline 
characteristics 
available upon 
request 
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7.1.d: Justify how events are 
attributed to current, prior, ever, or 
cumulative drug exposure. 
7.1.e: When examining drug dose 
and risk attribution, describe how 
current, historical or time on therapy 
are considered. 
7.1.f: Use of any comparator groups 
should be outlined and justified. 
7.1.g: Outline the approach used to 
handle individuals with more than 
one relevant drug exposure during 
the study period. 
Data sources/measurement 
8 For each variable of interest, give 
sources of data and details of 
methods of assessment 
(measurement). Describe 
comparability of assessment 
methods if there is more than one 
group. 
 8.a: Describe the healthcare system 
and mechanisms for generating the 
drug exposure records. Specify the 
care setting in which the drug(s) of 
interest was prescribed. 
Chapter 4 
Bias 
9 Describe any efforts to address 
potential sources of bias. 
— — Chapter 4 
Chapter 6 
Study size 
10 Explain how the study size was 
arrived at. 
— — Chapter 5: 
Figure 1 
Quantitative variables 
11 Explain how quantitative variables 
were handled in the analyses. If 
— —  
Chapter 4 
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applicable, describe which 
groupings were chosen, and why. 
Statistical methods 
 (a) Describe all statistical methods, 
including those used to control for 
confounding. 
(b) Describe any methods used to 
examine subgroups and interactions. 
(c) Explain how missing data were 
addressed. 
(d) Cohort study—if applicable, 
explain how loss to follow-up was 
addressed. 
Case-control study—if applicable, 
explain how matching of cases and 
controls was addressed. Cross 
sectional study—if applicable, 
describe analytical methods taking 
account of sampling strategy. 
(e) Describe any sensitivity 
analyses. 
— 12.1.a: Describe the methods used to 
evaluate whether the assumptions 
have been met. 
12.1.b: Describe and justify the use 
of multiple designs, design features, 
or analytical approaches. 
 
Chapter 4 
Data access and cleaning methods 
12 — 12.1: Authors should describe 
the 
extent to which the 
investigators 
had access to the database 
population used to create the 
study population. 
12.2: Authors should provide 
information on the data 
— 
N/A 
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cleaning methods used in the 
study. 
Linkage 
12 — 12.3: State whether the study 
included person level, 
institutional level, or other 
data linkage across two or 
more databases. The methods 
of linkage and methods of 
linkage quality evaluation 
should be provided. 
— 
Chapter 4 
Results 
Participants 
13 (a) Report the numbers of 
individuals at each stage of the 
study (eg, numbers potentially 
eligible, examined for eligibility, 
confirmed eligible, included in the 
study, completing follow-up, and 
analysed). 
(b) Give reasons for non-
participation at each stage. 
(c) Consider use of a flow diagram. 
13.1: Describe in detail the 
selection of the individuals 
included in the study (that is, 
study population selection) 
including filtering based on 
data quality, data availability, 
and linkage. The selection of 
included individuals can be 
described in the text or by 
means of the study flow 
diagram. 
— 
Chapter 5: 
Figure 1 
Descriptive 
data 
    
14 (a) Give characteristics of study 
participants (eg, demographic, 
clinical, social) and information on 
exposures and potential 
— — 
Chapter 5: 
Table 2 
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confounders. 
(b) Indicate the number of 
participants with missing data for 
each variable of interest. 
(c) Cohort study—summarise 
follow-up time (eg, average and 
total amount). 
Outcome data 
15 Cohort study—report numbers of 
outcome events or summary 
measures over time. 
Case-control study—report numbers 
in each exposure category, or 
summary measures of exposure. 
Cross sectional study—report 
numbers of outcome events or 
summary measures. 
— — 
Chapter 5: 
Table 3 
Main results 
16 (a) Give unadjusted estimates and, if 
applicable, confounder adjusted 
estimates and their precision (eg, 
95% confidence intervals). Make 
clear which confounders were 
adjusted for and why they were 
included. 
(b) Report category boundaries 
when continuous variables are 
categorised. 
(c) If relevant, consider translating 
estimates of relative risk into 
absolute risk for a meaningful time 
— — 
Chapter 5: 
Table 3 
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period. 
Other analyses 
17 Report other analyses done—eg, 
analyses of subgroups and 
interactions, and sensitivity 
analyses. 
— — Chapter 5: 
Figure 2  
Appendices I-
M 
Discussion 
Key results 
18 Summarise key results with 
reference to study objectives. 
— — 
Chapter 6 
Limitations 
19 Discuss limitations of the study, 
taking into account sources of 
potential bias or imprecision. 
Discuss both direction and 
magnitude of any potential bias. 
19.1: Discuss the implications 
of using data that were not 
created or collected to answer 
the specific research 
question(s). Include discussion 
of misclassification bias, 
unmeasured confounding, 
missing data, and changing 
eligibility over time, as they 
pertain to the study being 
reported. 
19.1.a: Describe the degree to which 
the chosen database(s) adequately 
captures the drug exposure(s) of 
interest. 
Chapter 6 
Interpretation 
20 Give a cautious overall 
interpretation of results considering 
objectives, limitations, multiplicity 
of analyses, results from similar 
studies, and other relevant evidence. 
— 20.a: Discuss the potential for 
confounding by indication, 
contraindication or disease severity 
or selection bias (healthy 
adherer/sick stopper) as alternative 
explanations for the study findings 
when relevant.  
Chapter 6 
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Generalisability 
21 Discuss the generalisability 
(external validity) of the study 
results. 
— — 
Chapter 6 
Other information 
Funding 
22 Give the source of funding and the 
role of 
the funders for the present study 
and, if applicable, for the original 
study on which the present article is 
based. 
— — 
N/A 
Accessibility of protocol, raw data, and programming code 
22 — 22.1: Authors should provide 
information on how to access 
any supplemental information 
such as the study protocol, raw 
data, or programming code. 
— 
N/A 
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Appendix E. Coding definitions for demographics, comorbid conditions, healthcare 
utilization measures and laboratory measurements 
 
Variable Database Codes 
Demographics 
Age RPDB  
Sex RPDB  
Location of residence – 
Rural status 
RPDB RURAL 
Socioeconomic status 
(neighbourhood income 
quintiles) 
RPDB INCQUINT 
Local Health Integration 
Network (LHIN) 
RPDB LHIN 
Entry year   
Prescribing physician IPDB MAINSPECIALTY 
Comorbidities 
Duration of diabetes ODD  
Acute kidney injury  CIHI-DAD ICD-10: N17 
Chronic kidney disease CIHI-DAD  
 
OHIP 
ICD-10: E102, E112, E132, E142, I12, 
I13, N00, N01, N02, N03, N04, N05, N06, 
N07, N08, N10, N11, N12, N13, N14, 
N15, N16, N17, N18, N19, N20, N21, 
N22, N23 
OHIP dx: 403, 585 
Acute urinary retention CIHI-DAD ICD-10: R33 
Chronic obstructive 
pulmonary disease 
CIHI-DAD ICD-10: J41, J43, J44 
Chronic lung disease  CIHI-DAD 
 
CIHI-
NACRS 
 
OHIP 
ICD-10: I272, I278, I279, J40, J41, J42, 
J43, J44, J45, J47, J60, J61, J62, J63, J64, 
J65, J66, J67, J68, J701, J703, J704, J708, 
J709, J82, J84, J92, J941, J949, J953, 
J961, J969, J984, J988, J989, J99 
OHIP dx: 491, 492, 493, 494, 496, 501, 
502, 515, 518, 519 
OHIP fee: J889, J689 
Cancer  CIHI-DAD 
 
OHIP 
ICD-10: 80003, 80006, 80013, 80023, 
80033, 80043, 80102, 80103, 80106, 
80113, 80123, 802, 803, 80413, 80423, 
80433, 80443, 80453, 80502, 80503, 
80513, 80523, 807, 808, 80903, 80913, 
80923, 80933, 80943, 80953, 81103, 
81202, 81203, 81213, 81223, 81233, 
81243, 81303, 81402, 81403, 81406, 
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81413, 81423, 81433, 81443, 81453, 
81473, 81503, 81513, 81523, 81533, 
81543, 81553, 81603, 81613, 81623, 
81703, 81713, 81803, 81903, 82003, 
82013, 82102, 82103, 82113, 82203, 
82213, 823, 82403, 82413, 82433, 82443, 
82453, 82463, 82473, 82503, 82513, 
82603, 82612, 82613, 82623, 82632, 
82633, 82703, 82803, 82813, 82903, 
83003, 83103, 83123, 83143, 83153, 
83203, 83223, 83233, 83303, 83313, 
83323, 83403, 83503, 83703, 83803, 
83813, 83903, 84003, 84013, 84103, 
84203, 84303, 84403, 84413, 84423, 
84503, 84513, 84603, 84613, 84623, 
84703, 84713, 84723, 84733, 84803, 
84806, 84813, 849, 85002, 85003, 85012, 
85013, 85023, 85032, 85033, 85042, 
85043, 851, 852, 85303, 854, 85503, 
85603, 85623, 857, 85803, 86003, 86203, 
86303, 86403, 86503, 86803, 86933, 
87003, 87103, 87202, 87203, 87213, 
87223, 87233, 87303, 87403, 87412, 
87413, 87422, 87423, 87433, 87443, 
87453, 87613, 87703, 87713, 87723, 
87733, 87743, 87803, 88003, 88006, 
88013, 88023, 88033, 88043, 88103, 
88113, 88123, 88133, 88143, 88303, 
88323, 88333, 88403, 88503, 88513, 
88523, 88533, 88543, 88553, 88583, 
88903, 88913, 88943, 88953, 88963, 
89003, 89013, 89023, 89103, 89203, 
89303, 89333, 89403, 89413, 895, 89603, 
89633, 89643, 897, 89803, 89813, 89903, 
89913, 90003, 90203, 90403, 90413, 
90423, 90433, 90443, 90503, 90513, 
90523, 90533,  
906, 90703, 90713, 90723, 90803, 90813, 
90823, 90833, 90843, 90853, 90903, 
91003, 91013, 91023, 91103, 91203, 
91243, 91303, 91333, 91403, 91503, 
91703, 91803, 91813, 91823, 91833, 
91843, 91853, 91903, 92203, 92213, 
92303, 92313, 92403, 92503, 92513, 
92603, 92613, 92703, 92903, 93103, 
93303, 93623, 93643, 93703, 93803, 
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93813, 93823, 93903, 93913, 93923, 940, 
941, 942, 94303, 944, 945, 94603, 947, 
948, 94903, 95003, 95013, 95023, 95033, 
95043, 951, 952, 95303, 95393, 95403, 
95603, 95613, 95803, 95813, 959, 965, 
966, 967, 968, 969, 970, 971, 972, 973, 
97403, 97413, 97603, 97613, 97623, 
97633, 97643, 980, 982, 98303, 984, 
98503, 986, 98703, 98803, 989, 99003, 
99103, 993, 994, C00, C01, C02, C03, 
C04, C05, C06, C07, C08, C09, C10, C11, 
C12, C13, C14, C15, C16, C17, C18, C19, 
C20, C21, C22, C23, C24, C25, C26, C30, 
C31, C32, C33, C34, C37, C38, C39, C40, 
C41, C43, C44, C45, C46, C47, C48, C49, 
C50, C51, C52, C53, C54, C55, C56, C57, 
C58, C60, C61, C62, C63, C64, C65, C66, 
C67, C68, C69, C70, C71, C72, C73, C74, 
C75, C76, C77, C78, C79, C80, C81, C82, 
C83, C84, C85, C86, C88, C90, C91, C92, 
C93, C94, C95, C96, C97, D00, D01, D02, 
D03, D04, D05, D06, D07, D09, Z85 
OHIP dx: 140, 141, 142, 143, 144, 145, 
146, 147, 148, 149, 150, 151, 152, 153, 
154, 155, 156, 157, 158, 159, 160, 161, 
162, 163, 164,165, 170, 171, 172, 173, 
174, 175, 179, 180, 181, 182, 183, 184, 
185, 186, 187, 188, 189, 190, 191, 192, 
193, 194, 195, 196, 197, 198, 199, 200, 
201, 202, 203, 204, 205, 206, 207, 208, 
230, 231, 232, 233, 234 
Stroke  CIHI-DAD ICD-10: I62, I630, I631, I632, I633, I634, 
I635, I638, I639, I64, H341, I600, I601, 
I602, I603, I604, I605, I606, I607, I609, 
I61, G450, G451, G452, G453, G458, 
G459, H340 
 
Atrial fibrillation CIHI-DAD ICD-10: I48 
Ventricular arrhythmia CIHI-DAD 
 
NACRS 
ICD-10: I472, I4900 
Coronary artery bypass 
graft surgery 
CIHI-DAD 
 
OHIP 
CCI: 1IJ76 
OHIP fee: R742, R743, E654, E645, E652, 
E646 
Percutaneous coronary 
intervention 
CIHI-DAD 
 
CCI: 1IJ50, 1IJ57GQ, 1IJ54GQAZ 
OHIP fee: Z434, G262, G298 
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OHIP 
Pacemaker CIHI-DAD 
 
CIHI-
NACRS 
 
OHIP 
CCI: 1HZ37, 1HD53GRJA, 1HD54GRJA, 
1HZ53GRNK, 1HZ53GRNL, 
1HZ53GRNM, 1HZ54LANJ, 2HZ07NK 
2HZ07NL, 2HZ07NM, 1HZ53GRFR, 
1HZ53LAFR, 1HZ53SYFR, 1HD55, 
1HZ09, 1HZ55, 2HZ24, 1Hz53GRNN 
OHIP fee: G303, Z433, Z435, Z443, Z444, 
Z445, R752, Z412, Z428, E628, G176, 
G177, G115 
Congestive heart failure CIHI-DAD 
 
OHIP 
ICD-10: I099, I420, I425, I426, I427, I428, 
I429, I43, I500, I501, I509, I255, J81 
CCP: 4961, 4962, 4963, 4964 
CCI: 1HP53, 1HP55, 1HZ53GRFR, 
1HZ53LAFR, 1HZ53SYFR 
OHIP fee: R701, R702, Z429 
OHIP dx: 428 
Transplant - hepatic  CIHI-DAD 
 
OHIP 
ICD-10: T86400, T86401, T86402, Z944, 
CCI: 1OA85 
OHIP fee: S294, S295, E765, G254 
Chronic liver disease CIHI-DAD 
 
OHIP 
ICD-10: B16, B17, B18, B19, I85, R17, 
R18, R160, R162, B942, Z225, E831, 
E830, K70, K713, K714, K715, K717, 
K721, K729, K73, K74, K753, K754, 
K758, K759, K76, K77 
OHIP dx: 571, 573, 070 
OHIP fee: Z551, Z554 
Coronary artery disease CIHI-DAD 
 
OHIP 
ICD-10: I20, I21, I22, I23, I24, I25, Z955, 
Z958, Z959, R931, T822 
CCI: 1IJ26, 1IJ27, 1IJ54, 1IJ57, 1IJ50, 
1IJ76 
CCP: 4801, 4802, 4803, 4804, 4805, 481, 
482, 483 
OHIP fee: R741, R742, R743, G298, 
E646, E651, E652, E654, E655, G262, 
Z434, Z448 
OHIP dx: 410, 412, 413 
Diabetic retinopathy  CIHI-DAD ICD-10: E1030, E1031, E1032, E1033, 
E1130, E1131, E1132, E1133, E1330, 
E1331, E1332, E1333, E1430, E1431, 
E1432, E1433, H360 
 
Diabetic neuropathy CIHI-DAD ICD-10: E1040, E1041, E1042, E1048, 
E1049, E1440, E1441, E1442, E1448, 
E1140, E1141, E1142, E1148, E1340, 
E1341, E1342, E1348, E1349, G590, 
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G632, G990 
Peripheral vascular disease CIHI-DAD 
 
OHIP 
ICD-10: I700, I702, I708, I709, I731, I738, 
I739, K551 
CCP: 5125, 5129, 5014, 5016, 5018, 5028, 
5038, 5126, 5159 
CCI: 1KA76, 1KA50, 1KE76, 1KG50, 
1KG57, 1KG76MI, 1KG87, 1IA87LA, 
1IB87LA, 1IC87LA, 1ID87, 1KA87LA, 
1KE57 
OHIP fee: R787, R780, R797, R804, 
R809, R875, R815, R936, R783, R784, 
R785, E626, R814, R786, R937, R860, 
R861, R855, R856, R933, R934, R791, 
E672, R794, R813, R867, E649 
Hypertension  ODB  
Hypotension  CIHI-DAD ICD-10: I95 
Hypoglycemia  CIHI-DAD ICD-10: E15, E160, E161, E162, E1063, 
E1163, E1363, E1463 
Hyperglycemic emergency CIHI-DAD ICD-10: E1410, E1412, E1010, E1012, 
E1110, E1112, E1300, E140 
Hyponatremia  CIHI-DAD ICD-10: E871 
Influenza vaccination OHIP OHIP fee: G590, G591 
Respiratory infection CIHI-DAD 
 
OHIP 
ICD-10: 462, 5191, 5180, 5181, 5812, 
51889, 5192, 5193, 5194, 5198, 5199, 
3821, 3822, 3823, 3824, 3829, 463, 4660, 
485, 481, 514, 486, 4919, 4650, 4658, 
4659, 4740, 4741, 4749, 4610, 4611, 4612, 
4613, 4618, 4619, 496, 0340 
ICD-10: J22, J02, J98, H66, J03, H65, J20, 
J18, J42, J06, J35, J01, J44 
OHIP dx: 519, 460, 382, 463, 381, 466, 
486, 491, 474, 461, 496, 034 
Skin & soft tissue infection CIHI-DAD 
 
OHIP 
ICD-10: L08, L03, T01, L01, T814, A46 
OHIP dx: 709, 686, 698, 682, 998, 879, 
894, 884, 684, 250 
Infections, other CIHI-DAD 
 
OHIP 
ICD-10: A49 
OHIP dx: 786, 136, 040, 039 
Hyperkalemia  CIHI-DAD ICD-10: E875 
Urinary incontinence  CIHI-DAD ICD-10: N393, N394, R32 
Urinary retention CIHI-DAD ICD-10: R33 
Urinary tract infections CIHI-DAD ICD-10: N10, N11, N12, n136, N151, 
N159, N160, N300, N308, N309, N340, 
N390, N410, N411, N412, N413, N431, 
N45, T835 
Charlson comorbidity index CIHI-DAD  
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Healthcare Utilization 
Number of any 
hospitalizations 
CIHI-DAD  
Number of any emergency 
room visits  
NACRS  
GP/FP visits OHIP  
 
IPDB 
 
Cardiologist visits  IPDB  
Opthamologist vists  IPDB  
Endocrinologist vists IPDB  
Nephrologist visits  OHIP 
 
IPDB 
 
Diabetes management OHIP OHIP fee: K030 
Diabetes incentive OHIP OHIP fee: Q040 
Diabetes management by a 
specialist 
OHIP OHIP fee: K045 
Diabetes management by a 
specialist team 
OHIP OHIP fee: K046 
Cholesterol tests OHIP OHIP fee: L055 
Proteinuria OHIP OHIP fee: L253, L254, L255, G009, G010 
Serum creatine tests OHIP OHIP fee: L065, L067, L068 
Glucose tests OHIP OHIP fee: L104, L253, L103, L111 
HbA1c tests  OHIP OHIP fee: L093 
DVT/PE CIHI-DAD ICD-10: I26, I743, I801, I802, I803 
Bone mineral density test OHIP OHIP fee: J654, J688, J854, J888, X149, 
X152, X153, X155, Y654, Y688, Y854, 
Y888 
Hearing test  OHIP OHIP fee: G153, G154, G440, G441, 
G442, G443, G448, G450, G451, G452, 
G525, G526, G529, G530, G533, G815, 
G816 
Sputum OHIP OHIP fee: L629, L716, L815 
Wound swab  OHIP OHIP fee: L628 
Holter monitoring  CIHI-DAD 
 
OHIP 
CCI: 2HZ24JAKH 
OHIP fee: G311, G320, G647, G648, 
G649, G650, G651, G652, G653, G654, 
G655, G656, G657, G658, G659, G660, 
G661, G682, G683, G684, G685, G686, 
G687, G688, G689, G690, G692, G693 
Cardiac stress test CIHI-DAD 
 
OHIP 
CCP: 0341, 0342, 0343, 0344, 0605 
CCI: 2HZ08, 3IP70 
OHIP fee: G315, G174, G111, G112, 
G319, G582, G583, G584, J607, J608, 
J807, J808, J809, J866, J609, J666 
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Coronary revascularization CIHI-DAD 
 
OHIP 
CCP: 481, 482, 483, 480 
CCI: 1IJ50, 1IJ26, IIJ27, 1IJ57, 1IJ76, 
1IJ57GQ, 1IJ54GQAZ  
OHIP fee: R741, R742, R743, E651, E652, 
E654, E646, G298, Z434, G262 
Electrocardiography CIHI-DAD  
 
OHIP 
CCI: 2HZ24JAKE 
OHIP fee: G310, G313 
Pulmonary function test OHIP OHIP fee: L354, L358 
At-home physician service OHIP OHIP fee: A901, B960, B961, B962, 
B963, B964, B966, B990, B992, B993, 
B994, B996, B997, B998 
Urinalysis  OHIP OHIP Fee: L253, L254, L255, L633, 
L634, L641, G009, G010 
Cystoscopy OHIP OHIP fee: Z606, Z607, Z628, Z632, Z633, 
Z634 
Transurethral resection of 
the prostate  
CIHI-DAD 
 
OHIP 
CCI: 1QT59BAAD, 1QT59BAAG, 
1QT59BAAW, 1QT59BAAZ, 
1QT59BACG, 1QT59BAGX, 1QT87BA, 
1QT87BAAG, 1QT87BAAK 
CCP: 721 
OHIP fee: S655 
Carotid ultrasound  CIHI-DAD 
 
OHIP 
CCP: 0281 
CCI: 3JE30, 3JG30 
OHIP fee: J201, J501, J190, J191, J490, 
J491, J492 
Cardiac catheterization CIHI-DAD 
 
OHIP 
CCP: 4995, 4996, 4997, 4892, 4893, 4894, 
4895, 4896, 4897, 4898 
CCI: 3IJ30GP, 3HZ30GP, 2HZ24GPKJ, 
2HZ24GPKL, 2HZ24GPKM, 
2HZ24GPXJ, 2HZ28GPPL, 2HZ71GP, 
3IP10, 3IS10 
OHIP fee: G296, G297, G299, G300, 
G301, G304, G305, G306, G297, G509 
Coronary angiogram  CIHI-DAD 
 
OHIP 
CCP: 4892, 4893, 4894, 4895, 4896, 4897, 
4898 
CCI: 3IP10, 3IS10 
OHIP fee: G297, G509 
Electroencephalography 
(EEG)  
OHIP OHIP fee: G414, G415, G416, G417, 
G418, G540, G542, G544, G545, G546, 
G554, G555 
Chest x-ray  OHIP OHIP fee: X090, X091, X092, X195 
Echocardiography CIHI-DAD 
 
OHIP 
CCP: 0282  
CCI: 3IP30 
OHIP fee: G560, G561, G562, G566, 
G567, G568, G570, G571, G572, G574, 
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G575, G576, G577, G578, G581 
Prostate-specific antigen 
test  
OHIP OHIP fee: Q005, Q118, Q119, Q120, 
Q121, Q122, Q123, Q133 
Cervical cancer screening OHIP OHIP fee: E430, G365, G394, L713, L812 
Laboratory Measurements 
eGFR (using serum 
creatinine) 
OLIS  
Serum creatinine OLIS OLIS: 14682-9 
Serum potassium  OLIS OLIS: 2823-3, 6298-4,39789-3 
Albumin-to-creatinine ratio OLIS OLIS: 14959-1, 30000-4, 32294-1 
Glycated hemoglobin  OLIS OLIS: 4548-4, 71875-9, 59261-8, 17855-8, 
17856-6, 41995-2 
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Appendix F. Variables included in the propensity score 
 
Variables included in the propensity score 
Demographics 
Age 
Sex 
Entry year  
Rural residence 
Neighbourhood income quintile  
Local Health Integration Network  
Comorbidities 
Duration of diabetes 
Acute kidney injury  
Chronic kidney disease 
Acute urinary retention 
Chronic obstructive pulmonary disease 
Chronic lung disease  
Percutaneous coronary intervention 
Pacemaker  
Cancer 
Stroke  
Atrial fibrillation 
Ventricular arrhythmia 
Coronary artery bypass graft surgery 
Congestive heart failure 
Chronic liver disease  
Coronary artery disease  
Diabetic retinopathy  
Diabetic neuropathy  
Peripheral vascular disease  
Hypertension 
Hypotension 
Hypoglycemia  
Hyponatremia 
Hyperkalemia  
Charlson comorbidity index  
Medications 
Angiotensin-converting enzyme inhibitors 
Angiotensin receptor blockers 
Acetylsalicyclic acid 
Beta blockers 
Calcium channel blockers  
Loop diuretics   
Potassium sparing diuretics 
Nonsteroidal anti-inflammatory drugs 
Statins  
Thiazide diuretics  
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Proton pump inhibitors  
Picosalax 
Insulin use 120 days prior to the cohort 
entry date 
Acarbose use 120 days prior to the cohort 
entry date 
Gliclazide use120 days prior to the cohort 
entry date 
Glyburide use 120 days prior to the cohort 
entry date 
Metformin use 120 days prior to the cohort 
entry date  
Pioglitazine use 120 days prior  
Insulin use on the cohort entry date 
Acarbose use on the cohort entry date 
Gliclazide use on the cohort entry date 
Glyburide use on the cohort entry date 
Metformin use on the cohort entry date 
Insulin use in the 1 year to 120 days prior to 
the cohort entry date 
Acarbose use in the 1 year to 120 days prior 
to the cohort entry date 
Gliclazide use in the 1 year to 120 days 
prior to the cohort entry date 
Glyburide use in the 1 year to 120 days prior 
to the cohort entry date 
Metformin use in the 1 year to 120 days 
prior to the cohort entry date 
Pioglitazine use in the 1 year to 120 days 
prior to the cohort entry date 
Healthcare Utilization 
Number of any hospitalizations 
Number of emergency department visits  
Number of general practice or family 
practice visits 
Number of cardiologist visits 
Number of opthamologist visits 
Number of endocrinologist visits 
Number of nephrologist visits  
Diabetes management  
Diabetes incentive  
Diabetes management by a specialist  
Diabetes management by a specialist team 
Cholesterol test 
Proteinuria  
Serum creatinine test 
Glucose test 
83 
 
 
Glycated hemoglobin test 
Bone mineral density test 
Hearing test 
Holter monitoring 
Cardiac stress test  
Coronary revascularization  
Electrocardiography  
Pulmonary function test  
At-home physician service 
Urinalysis 
Cystoscopy  
Carotid ultrasound 
Cardiac catheterization 
Coronary angiogram 
Electroencephalography 
Chest x-ray  
Echocardiography 
Prostate-specific antigen test  
Cervical cancer screening  
Other 
Prescribing physician specialty  
Number of medications 
Estimated baseline glomerular filtration rate 
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Appendix G. 2012 KDIGO thresholds for AKI stages (27) 
 
Stage Definition 
1 
50 to <100% increase in serum creatinine from baseline or an absolute 
increase ≥0.3 mg/dL, but does not meet stage two or three criteria 
2 100 to <200% increase from baseline 
3 
≥200% increase from baseline, absolute serum creatinine value of 4.0 
mg/dL, or receipt of acute dialysis 
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Appendix H. ACE inhibitors, ARBs and all type of diuretic drugs included in the 
subgroup analysis 
 
Drug Name  Drug Identification Numbers 
ACE inhibitor 
Captopril 00546283, 00546291, 00546305, 00695661, 00851639, 00851647, 
00851655, 00851833, 00893595, 00893609, 00893617, 00893625, 
01913824, 01913832, 01913840, 01913859, 01942964, 01942972, 
01942980, 01942999, 02163551, 02163578, 02163586, 02163594, 
02230203, 02230204, 02230205, 02230206, 02237861, 02237862, 
02237863, 02242788, 02242789, 02242790, 02242791 
Lisinopril 00839329, 00839337, 00839388, 00839396, 00839418, 00839442, 
02049333, 02049376, 02049384, 02217481, 02217503, 02217511, 
02256797, 02256800, 02256819, 02271443, 02271451, 02271478, 
02274833, 02274841, 02274868, 02285061, 02285088, 02285096, 
02285118, 02285126, 02285134, 02289199, 02289202, 02289229, 
02292203, 02292211, 02292238, 02294230, 02294249, 02294257, 
02294591, 02299879, 02299887, 02299895, 02332167, 02332175, 
02332183, 02361531, 02361558, 02361566, 02394472, 02394480, 
02394499, 09853685, 09853960, 09854010, 09857272, 09857286, 
09857287 
Enalapril sodium  00670901, 00670928, 00708879, 00708887, 00851795, 02019884, 
02019892, 02019906, 02020025, 02233005, 02233006, 02233007, 
02291878, 02291886, 02291894, 02291908, 02299933, 02299941, 
02299968, 02299976, 02299984, 02299992, 02300001, 02300028, 
02300036, 02300044, 02300052, 02300060, 02300079, 02300087, 
02300095, 02300109, 02300117, 02300125, 02300133, 02300141, 
02300680, 02352230, 02352249, 02352257, 02352265 
Benazepril chlorohydrate  00885835, 00885843, 00885851 
Cilazapril 01911465, 01911473, 01911481, 02266350, 02266369, 02266377, 
02280442, 02280450, 02280469, 02283778, 02283786, 02283794, 
02285215, 02285223, 02291134, 02291142, 02291150 
Quinapril  01947664, 01947672, 01947680, 01947699, 02248499, 02248500, 
02248501, 02248502, 02290987, 02290995, 02291002, 02291010 
Ramipril 02050943, 02050951, 02050978, 02050986, 02221829, 02221837, 
02221845, 02221853, 02247917, 02247918, 02247919, 02247945, 
02247946, 02247947, 02251515, 02251531, 02251574, 02251582, 
02255316, 02255324, 02255332, 02283891, 02287692, 02287706, 
02287714, 02287722, 02287927, 02287935, 02287943, 02291398, 
02291401, 02291428, 02291436, 02295369, 02295482, 02295490, 
02295504, 02295512, 02299372, 02301148, 02301156, 02301164, 
02301172, 02310503, 02310511, 02310538, 02310546, 02331101, 
02331128, 02331136, 02331144, 02332299, 02332302, 02332310, 
02332329, 02374846, 02374854, 02374862, 02387387, 02387395, 
02387409, 02387417, 02420457, 02420465, 02420473, 02420481, 
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02421305, 02421313, 02421321, 02438860, 02438879, 02438887, 
02438895 
Perindopril tert-
butylamine 
02123274, 02123282, 02246624 
Trandolapril 02231459, 02231460, 02239267 
Fosinopril 02242733, 02242734, 02262401, 02262428, 02331004, 02331012 
Fosinopril sodium 02247802, 02247803, 02255944, 02255952, 02266008, 02266016, 
02275252, 02275260, 02294524, 02294532, 02332566, 02332574, 
01907107, 01907115 
Benazapril HCL 02273918, 02290332, 02290340 
Hydrochlorothiazide & 
Lisinopril 
02301768 
ARB 
Losartan potassium 02182815, 02182874, 02182882, 02309750, 02309769, 02309777, 
02313332, 02313340, 02313359, 02353504, 02353512, 02354829, 
02354837, 02354845, 02357968, 02357976, 02368277, 02368285, 
02368293, 02379058, 02380838, 02398834, 02398842, 02398850, 
02403323, 02403331, 02403358, 02404451, 02404478, 02404486, 
02405733, 02405741, 02405768, 02422468, 02422484, 02424967, 
02424975, 02424983, 02426595, 02426609, 02426617 
Valsartan 02236808, 02236809, 02244781, 02244782, 02289504, 02313006, 
02313014, 02337495, 02337509, 02337517, 02344564, 02356651, 
02356678, 02356686, 02356759, 02356767, 02356775, 02363100, 
02363119, 02371529, 02371537, 02371545, 02383535, 02383543, 
02383551, 02414228, 02414236, 02414244 
Irbesartan 02237923, 02237924, 02237925, 02315971, 02315998, 02316005, 
02316390, 02316404, 02316412, 02317060, 02317079, 02317087, 
02328070, 02328089, 02328100, 02328461, 02328488, 02328496, 
02347296, 02347318, 02347326, 02386968, 02386976, 02386984, 
02406810, 02406829, 02406837, 02418193, 02418207, 02418215, 
02422980, 02422999, 02423006, 02427087, 02427095, 02427109 
Candesartan Cilexetil 02239090, 02239091, 02239092, 02311658, 02326957, 02326965, 
02326973, 02365340, 02365359, 02365367, 02366312, 02366320, 
02366339, 02376520, 02376539, 02376547, 02376555, 02379120, 
02379139, 02379147, 02379155, 02379260, 02379279, 02379287, 
02379295, 02380684, 02380692, 02380706, 02380714, 02386496, 
02386518, 02386526, 02386534, 02391171, 02391198, 02391201, 
02391228, 02392267, 02399105, 02417340 
Eprosartan Mesylate 02240431, 02240432, 02243942 
Telmisartan 02240769, 02240770, 02320177, 02320185, 02375958, 02375966, 
02376717, 02376725, 02391236, 02391244, 02393247, 02393255, 
02407485, 02407493, 02420082, 02420090, 02432897, 02432900, 
02434164 
Eprosartan Mesylate & 
Hydrochlorothiazide 
02253631 
Olmesartan Medoxomil  02318660, 02318679 
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Hydrochlorothiazide & 
Quinopril 
02408775 
Hydrochlorothiazide & 
Telmisartan 
02433214 
Loop Diuretics 
Bumetanide 00728276, 00728284, 02176076 
Ethacrynic acid 00016497, 02258528 
Furosemide 00012580, 00217743, 00289590, 00332275, 00337730, 00337749, 
00344079, 00353612, 00362166, 00380016, 00380024, 00396249, 
00396788, 00432342, 00527033, 01900943, 01987585, 01987615, 
01987739, 01987798, 01988832, 02224690, 02224704, 02224720, 
02224755, 09857208 
Potassium Sparring Diuretics  
Amiloride HCL 00487805, 02249510 
Amiloride HCL & 
Hydrochlorothiazide 
00487813, 00784400, 00886106, 01937219, 02174596, 02257378 
Eplerenone 02323052, 02323060 
Hydrochlorothiazide & 
Spironolactone 
00180408, 00594377, 00613231, 00657182 
Hydrochlorothiazide & 
Trimolol Maleate 
00509353 
 
Hydrochlorothiazide & 
Triamterene 
00181528, 00441775, 00532657, 00865532, 01910191, 01919547 
Spironolactone 00028606, 00285455, 00613215, 00613223 
Triamterene 00027138, 00299715, 01919563, 01919571 
Thiazide Diuretics  
Chlorthalidone 00010413, 00010421, 00293881, 00298964, 00337447, 00337455, 
00360279, 00360287, 00398365, 00398373 
Hydrochlorothiazide  00016500, 00016519, 00021474, 00021482, 00092681, 00092703, 
00263907, 00312800, 00326844, 02247386, 02247387 
Indapamide 00564966, 02049341, 02153483, 02179709, 02223597, 02223678, 
02227339, 02231184, 02239619, 02239620, 02240067, 02245246, 
02373904, 02373912 
Metolazone 00301663, 00301671, 00301698, 00888400, 00888419, 00888427 
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Appendix I. Serum creatinine measurement during the follow-up period 
 
 
Observed Weightedb 
No. events (%) No. events (%) 
Risk difference, % 
(95% CI) 
Risk Ratio 
(95% CI) 
P 
value 
SGLT2 
inhibitors 
(n=19,611) 
DPP4 
inhibitors 
(n=19,483) 
SGLT2 
inhibitors 
(n=19,611) 
DPP4 
inhibitors 
(n=19,775) 
At least one 
serum 
creatinine 
measurementc 
10,619 (54.15) 9,602 (49.28) 
10,619 
(54.15) 
9,718 
(49.14) 
5.00 
(3.65 to 6.36) 
1.10 
(1.07 to 1.13) 
< 0.01 
 
Abbreviations: CI= confidence interval, DPP4= dipeptidyl peptidase-4, SGLT2= sodium-glucose cotransporter-2 
aReference group: DPP4 inhibitor users.  
bWeighted using inverse probability of treatment weighting based on propensity scores, using weights to estimate the average 
treatment effect in the treated. Patients in the reference group were weighted as [propensity score/(1 - propensity score)]. This method 
produces a weighted pseudo-sample of patients in the reference group with the same distribution of measured covariates as the 
exposure group (71,73,74). Weighted relative risks and 95% CIs were obtained using modified Poisson regression (88) and weighted 
risk differences and 95% CIs were obtained using a binomial regression model with an identity link function. 
cBased on tests done in an outpatient setting assessed using the Ontario Laboratories Information System serum creatinine values.
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aWeighted mean difference and 95% CIs were obtained using a normal regression model with an identity link function. 
SGLT2i users  
 Unit change (weighted) 
N Mean (SD) 95% CI Median 
(IQR) 
10,936 8 (26) 7-8 5 (-1,12) 
DPP4i users  
 Unit change (weighted) 
N Mean (SD) 95% CI Median 
(IQR) 
10,070 7 (26) 6-7 4 (-2,11) 
Weighted mean difference p-
value Estimate 95% CI 
1 .01 0.30-1.71 0.005 
Appendix J. Absolute changes (µmol/L) in serum creatinine after SGLT2 inhibitor and DPP4 inhibitor initiation 
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aWeighted mean difference and 95% CIs were obtained using a normal regression model with an identity link function.  
DPP4i users  
 Unit change (weighted) 
N Mean (SD) 95% CI Median 
(IQR) 
10,070 9 (29) 8-9 5 (-3,14) 
Weighted mean difference p-
value Estimate 95% CI 
1.27  0.45-2.10 0.002 
SGLT2i users  
 Unit change (weighted) 
N Mean (SD) 95% CI Median 
(IQR) 
10,936 10 (32) 9-11 7 (-1,16) 
Appendix K. Percent changes in serum creatinine after SGLT2 inhibitor and DPP4 inhibitor initiation 
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Appendix L. Risk of hospital encounter with acute kidney injurya within 365 days among SGLT2 inhibitor new users compared with 
DPP4 inhibitor new users 
 
 
Observed Weightedc 
No. 
patients 
No. 
events 
(%) 
Event rate 
per 1000 
person-
years 
No. 
patients 
No. events 
(%) 
Event rate 
per 1000 
person-
years 
Hazard ratio 
(95% CI) 
P 
value 
SGLT2 
inhibitors 
19,611 
2,666 
(13.59) 
172.42 19,611 
2,666 
(13.59) 
172.42 
0.83 (0.78 to 
0.89)d 
<.0001 
DPP4 inhibitorsb 19,483 
3,712 
(19.05) 
245.77 19,775 
3,164 
(16.00) 
207.51 
 
Abbreviations: CI= confidence interval, DPP4= dipeptidyl peptidase-4, SGLT2= sodium-glucose cotransporter-2  
a365- day risk of acute kidney injury, based on hospital presentation (emergency department or hospitalization) assessed using the 
Ontario Laboratories Information System serum creatinine values.  
bReference group: DPP4 inhibitor users.  
cWeighted using inverse probability of treatment weighting based on propensity scores, using weights to estimate the average 
treatment effect in the treated. Patients in the reference group were weighted as [propensity score/(1 - propensity score)]. This method 
produces a weighted pseudo-sample of patients in the reference group with the same distribution of measured covariates as the 
exposure group (71,73,74).  
dWeighted hazard ratio and 95% CI were obtained using Cox regression (with 365-day follow-up censoring on death). A similar result 
was observed when death was treated as a competing risk. 95% CI was obtained using a bootstrap estimator (100). In addition, the 
proportional hazards assumption was tested by including time dependent covariates in the model and the assumption was not violated.
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Appendix M.  90-day risk of hospital encounter with bowel obstruction 
 
 
Observed Weightedb 
No. events (%) No. events (%) 
Risk difference, 
% 
(95% CI) 
P 
value 
Risk ratio 
(95% CI) 
P 
value 
SGLT2 
inhibitors 
(n=19,611) 
DPP4 
inhibitors 
(n=19,483) 
SGLT2 
inhibitors 
(n=19,611) 
DPP4 
inhibitors 
(n=19,775) 
Outcome 
Bowel 
obstructionc 
20 (0.10) 36 (0.18) 20 (0.10) 20 (0.10) 0 (-0.07 to 0.07) 1.00 
1.00 (0.49 to 
2.06) 
1.00 
 
Abbreviations: CI= confidence interval, DPP4= dipeptidyl peptidase-4, SGLT2= sodium-glucose cotransporter-2.  
aReference group: DPP4 inhibitor users.  
bWeighted using inverse probability of treatment weighting based on propensity scores, using weights to estimate the average 
treatment effect in the treated. Patients in the reference group were weighted as [propensity score/(1 - propensity score)].  This method 
produces a weighted pseudo-sample of patients in the reference group with the same distribution of measured covariates as the 
exposure group (71,73,74). Weighted risk ratios and 95% CIs were obtained using modified Poisson regression (88) and weighted risk 
differences and 95% CIs were obtained using a binomial regression model with an identity link function. 
cBased on hospital presentation (emergency department or hospitalization) assessed using diagnostic codes. 
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Appendix N. Post-hoc E-value analysis  
 
 
 
 
E-value for point estimate: 1.83 and for confidence interval: 1.14 
Each point along the curve defines a joint relationship between the two sensitivity 
parameters that could potentially explain away the estimated effect. If one of the two 
parameters is smaller than the E-value, the other must be larger, as defined by the plotted 
curve 
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